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Abstract 
 
Background 
 
An abnormal or persistent urge-to-cough is a common symptom of respiratory disease with few 
effective treatments. Evidence suggests that both cough and the urge-to-cough are particularly 
susceptible to placebo effects, indicating inhibitory processes in the central nervous system that are 
capable of reducing the urge-to-cough. Little is known about how these circuits are organised in the 
human brain. Knowledge of the neural basis of placebo inhibition of urge-to-cough may help to 
develop targets for future antitussive therapies. These studies investigate the effect of placebo on 
urge-to-cough using behavioural studies and functional magnetic resonance imaging (fMRI). 
 
Aims: 
 
1) To determine whether placebo conditioning can modulate the perception of capsaicin-
evoked urge-to-cough in human subjects.  
2) Using fMRI, to establish whether placebo induced reduction of the urge-to-cough causes a 
commensurate reduction in activity in cortical brain regions involved in sensing capsaicin-
evoked urge-to-cough, and to identify regions that may be involved in producing this effect. 
3) Using fMRI optimised for the brainstem, to establish if placebo induced reduction of the 
urge-to-cough also causes inhibition in subcortical regions involved in processing signals 
from the airways. 
 
Methods 
 
Three independent experiments were designed in which healthy adult volunteers underwent a series 
of inhalations of a substance that causes an urge-to-cough (capsaicin, the active ingredient in hot 
chilli peppers), preceded by either placebo treatment (via a placebo inert gas inhaler or normal air 
via a nasal cannula), which participants believed was a local anaesthetic, or no treatment. 
Participants rated their urge-to-cough following each capsaicin inhalation period. Prior to the 
sessions participants were conditioned to believe the treatment would be effective by surreptitiously 
lowering the dose of capsaicin following placebo administration. Three separate cohorts completed 
the protocol. The first experiment (Chapter 3) optimised a protocol to test whether the 
psychophysical aspects of capsaicin-evoked urge-to-cough were modifiable by placebo 
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intervention. The second experiment (Chapter 4) then employed this protocol along with blood-
oxygen-level dependent (BOLD) fMRI to detect changes in cortical activation that accompanied the 
placebo response, while the third experiment (Chapter 5) used BOLD fMRI optimised for assessing 
subcortical and brainstem responses. 
 
Results 
 
Placebo administration resulted in a significant (up to 40 percent) reduction in participants’ ratings 
of urge-to-cough. fMRI showed capsaicin-evoked activations in a network of regions including 
primary motor and sensory cortices, supplementary motor area, insula, mid cingulate cortex and 
orbitofrontal cortex. Placebo administration significantly reduced BOLD signal responses following 
placebo treatment in a distributed network of cortical regions that are normally activated during 
capsaicin inhalation, including primary and secondary somatosensory cortex, primary motor cortex, 
mid cingulate cortex and supplementary motor area. Regions in the dorsolateral prefrontal and 
posterior parietal cortices that have been implicated in producing placebo analgesia also showed 
increased activation following placebo treatment. In the dorsolateral prefrontal cortex the magnitude 
of the activation was significantly correlated with the magnitude of placebo effect in individuals. 
This reduction in capsaicin-evoked activation following placebo was also observed in the pons and 
rostral medulla in the brainstem. 
 
Conclusions 
 
These studies are the first to confirm that administration of a placebo can alter perception of 
experimentally-evoked urge-to-cough. They also provide further evidence that higher brain 
networks are important in modulating responses to airway irritation. Consistent with subjective 
reports, placebo administration decreases capsaicin-related activation in brain regions that process 
incoming sensory signals from the airways. This indicates that placebo treatment is capable of 
activating endogenous inhibitory networks in the central nervous system that can suppress the 
sensation of airway irritation. This process is likely to be mediated by higher cortical regions, such 
as dorsolateral prefrontal cortex, that can suppress processing of incoming sensory signals from the 
airways by descending inhibition of brainstem respiratory centres. 
 
 
 iv 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the General Award Rules of The University of Queensland, immediately made available 
for research and study in accordance with the Copyright Act 1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
 v 
Publications during candidature 
 
Peer Reviewed Papers 
 
Leech J, Mazzone SB, Farrell MJ. The effect of placebo conditioning on capsaicin-evoked urge to 
cough. Chest 2012; 142: 951-957. 
 
Leech J, Mazzone SB, Farrell MJ. Brain Activity Associated with Placebo Suppression of the 
Urge-to-Cough in Humans. Am J Respir Crit Care Med 2013; 188: 1069-1075. 
 
Mazzone, S. B., McGovern, A. E., Yang, S. K., Woo, A., Phipps, S., Ando, A., Leech, J. Farrell, 
M. J. (2013). Sensorimotor Circuitry Involved in the Higher Brain Control of Coughing. 
Cough, 9(1), 7. 
 
Conference Abstracts 
 
Leech J, Farrell MJ, Mazzone SB. The effect of placebo conditioning on regional brain blood 
oxygen-level dependent signal changes during capsaicin-evoked urge-to-cough. Australian 
Neuroscience Society Annual Conference 2013; ORAL-20-08. 
 
  
 vi 
Publications included in this thesis 
 
Leech J, Mazzone SB, Farrell MJ. The effect of placebo conditioning on capsaicin-evoked urge to 
cough. Chest 2012; 142: 951-957 – Incorporated as Chapter 3. 
 
Contributor Statement of contribution 
Leech, J Designed experiments (70%) 
Wrote the paper (100%) 
Edited paper (50%) 
Interpreted results (50%) 
Mazzone, S.B. Edited paper (25%) 
Interpreted results (25%) 
Farrell, M.J. Designed experiments (30%) 
Edited paper (25%) 
Interpreted results (25%) 
 
 
Leech J, Mazzone SB, Farrell MJ. Brain Activity Associated with Placebo Suppression of the Urge-
to-Cough in Humans. Am J Respir Crit Care Med 2013; 188: 1069-1075 – incorporated as 
Chapter 4. 
 
Contributor Statement of contribution 
Leech, J. Designed experiments (80%) 
Wrote the paper (100%) 
Edited the paper (50%) 
Preparation of tables and figures (40%) 
Interpreted results (50%) 
Mazzone, S.B. Edited paper (25%) 
Interpretation of results (25%) 
Farrell, M.J. Designed experiments (20%) 
Edited paper (25%) 
Interpreted results (25%) 
Preparation of tables and figures (60%) 
 
 vii 
 
Contributions by others to the thesis  
 
Dr Farrell provided significant contributions to the design of the project and assistance with fMRI 
analysis and interpretation of data. Dr Mazzone contributed significantly to the conception of the 
project and provided assistance with interpretation of data and preparation of manuscripts. Dr 
Leonie Cole provided assistance with experimental design. Ms Ayaka Ando and Ms Camille 
Shanahan provided assistance with data collection. Dr Michael Kean contributed technical expertise 
related to fMRI data acquisition. 
 
 
Statement of parts of the thesis submitted to qualify for the award of another 
degree 
 
None 
 
 viii 
Acknowledgements 
 
I would like to acknowledge the financial support of the Australian Government through the 
Australian Postgraduate Awards scholarship, without which I would have been unable to complete 
this work, as well as the support of the University of Queensland, the Florey Institute of 
Neuroscience and Mental Health and the radiology staff at the Royal Children’s Hospital, 
Melbourne. 
 
I am immensely grateful for the time and support of my supervisors, Dr Farrell and Dr Mazzone, 
who have been endlessly patient and always enthusiastic, and have made this journey a highly 
rewarding one, as well as all of the members of the Neuroimaging Lab at the Florey Institute who 
provided invaluable friendship and support throughout my candidature, in particular Ayaka Ando 
and Camille Shanahan. I also would like to thank all of the participants who volunteered their time 
to be part of this study. 
 
Finally, I would like to thank Tricky, the love of my life. Without his endless support and laughter 
none of this would have been possible. 
 ix 
Keywords 
 
Neurosciences, neuroimaging, cough, urge-to-cough, capsaicin, placebo effect, functional magnetic 
resonance imaging, respiratory diseases. 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC code: 110903, Central Nervous System, 60% 
ANZSRC code: 110906, Sensory Systems, 20% 
ANZSRC code: 110203, Respiratory Diseases, 20% 
 
Fields of Research (FoR) Classification 
 
FoR code: 1109, Neurosciences, 80% 
FoR code: 1102, Cardiorespiratory Medicine and Haematology, 20% 
 
 
  
 x 
Table of Contents	  
 
ABSTRACT	  ...................................................................................................................................................................	  II	  
DECLARATION	  BY	  AUTHOR	  ..................................................................................................................................	  IV	  
PUBLICATIONS	  DURING	  CANDIDATURE	  ...........................................................................................................	  V	  
ACKNOWLEDGEMENTS	  .......................................................................................................................................	  VIII	  
LIST	  OF	  FIGURES	  ...................................................................................................................................................	  XIV	  
LIST	  OF	  TABLES	  .......................................................................................................................................................	  XV	  
LIST	  OF	  ABBREVIATIONS	  ...................................................................................................................................	  XVI	  
CHAPTER	  1	  -­‐	  INTRODUCTION	  ................................................................................................................................	  1	  COUGH	  ...............................................................................................................................................................................................	  1	  CLINICAL	  CONDITIONS	  INVOLVING	  ABNORMAL	  COUGH	  ..........................................................................................................	  2	  ANTITUSSIVE	  MEDICATIONS	  .........................................................................................................................................................	  2	  CHRONIC	  COUGH	  DISORDERS	  ........................................................................................................................................................	  2	  IDIOPATHIC	  COUGH	  .........................................................................................................................................................................	  3	  THE	  URGE-­‐TO-­‐COUGH	  ....................................................................................................................................................................	  4	  MODULATION	  OF	  THE	  URGE-­‐TO-­‐COUGH	  ....................................................................................................................................	  4	  PLACEBO	  MODULATION	  OF	  URGE-­‐TO-­‐COUGH	  ...........................................................................................................................	  5	  PLACEBO	  EFFECTS	  IN	  COUGH	  .......................................................................................................................................................	  5	  PLACEBO	  EFFECTS	  IN	  PAIN	  ...........................................................................................................................................................	  6	  MODELS	  OF	  PLACEBO	  EFFECT	  ......................................................................................................................................................	  6	  MODELS	  OF	  URGE-­‐TO-­‐COUGH	  ......................................................................................................................................................	  7	  CORTICAL	  MODULATION	  OF	  URGE-­‐TO-­‐COUGH	  .........................................................................................................................	  8	  FUNCTIONAL	  MAGNETIC	  RESONANCE	  IMAGING	  .......................................................................................................................	  9	  FUNCTIONAL	  NEUROANATOMY	  OF	  COUGH	  AND	  URGE-­‐TO-­‐COUGH	  .......................................................................................	  9	  FUNCTIONAL	  NEUROANATOMY	  OF	  PLACEBO	  EFFECT	  ...........................................................................................................	  12	  SUMMARY	  ......................................................................................................................................................................................	  14	  AIMS	  ................................................................................................................................................................................................	  14	  
Experiment	  1	  ..............................................................................................................................................................................	  14	  
Experiment	  2	  ..............................................................................................................................................................................	  14	  
Experiment	  3	  ..............................................................................................................................................................................	  15	  SIGNIFICANCE	  ................................................................................................................................................................................	  15	  
CHAPTER	  2	  -­‐	  METHODS	  -­‐	  EXPERIMENTAL	  DESIGN,	  FUNCTIONAL	  MAGNETIC	  RESONANCE	  
IMAGING	  AND	  ANALYSIS	  ......................................................................................................................................	  16	  OVERVIEW	  OF	  THE	  PRINCIPLES	  OF	  FMRI	  ................................................................................................................................	  16	  
 xi 
AIRWAY	  IRRITATIONS:	  	  MODELLING	  COUGH	  VERSUS	  THE	  URGE-­‐TO-­‐COUGH	  .....................................................................	  17	  CHOOSING	  A	  PLACEBO	  “TREATMENT”	  .....................................................................................................................................	  18	  DEVELOPMENT	  OF	  STUDY	  DESIGNS	  ..........................................................................................................................................	  19	  DEVELOPMENT	  OF	  PLACEBO	  MRI	  PROTOCOL	  ........................................................................................................................	  21	  DEVELOPMENT	  OF	  BRAINSTEM	  PLACEBO	  MRI	  PROTOCOL	  .................................................................................................	  23	  SUMMARY	  ......................................................................................................................................................................................	  25	  
CHAPTER	  3	  -­‐	  THE	  EFFECT	  OF	  PLACEBO	  CONDITIONING	  ON	  CAPSAICIN-­‐EVOKED	  URGE-­‐TO-­‐
COUGH	  ........................................................................................................................................................................	  26	  ABSTRACT	  ......................................................................................................................................................................................	  26	  INTRODUCTION	  .............................................................................................................................................................................	  27	  METHODS	  .......................................................................................................................................................................................	  28	  
Participants	  ................................................................................................................................................................................	  28	  
Capsaicin	  sensitivity	  testing	  ................................................................................................................................................	  28	  
Expectation	  .................................................................................................................................................................................	  29	  
Conditioning	  ...............................................................................................................................................................................	  29	  
Testing	  ...........................................................................................................................................................................................	  29	  
Effect	  of	  metered	  dose	  inhaler	  on	  urge-­‐to-­‐cough	  thresholds	  ................................................................................	  30	  
Statistical	  Methods	  ..................................................................................................................................................................	  30	  RESULTS	  .........................................................................................................................................................................................	  31	  
Participants	  ................................................................................................................................................................................	  31	  
Thresholds	  and	  Urge-­‐to-­‐Cough	  Ratings	  .........................................................................................................................	  31	  
Effect	  of	  metered	  dose	  inhaler	  on	  urge-­‐to-­‐cough	  ratings	  .......................................................................................	  35	  
Debriefing	  ....................................................................................................................................................................................	  35	  DISCUSSION	  ...................................................................................................................................................................................	  35	  CONCLUSIONS	  ................................................................................................................................................................................	  38	  
CHAPTER	  4	  -­‐	  BRAIN	  ACTIVITY	  ASSOCIATED	  WITH	  PLACEBO	  SUPPRESSION	  OF	  THE	  URGE-­‐TO-­‐
COUGH	  IN	  HUMANS	  ................................................................................................................................................	  39	  ABSTRACT	  ......................................................................................................................................................................................	  39	  INTRODUCTION	  .............................................................................................................................................................................	  40	  METHODS	  .......................................................................................................................................................................................	  41	  
Participants	  ................................................................................................................................................................................	  41	  
Capsaicin	  sensitivity	  testing	  ................................................................................................................................................	  41	  
Expectation,	  conditioning	  and	  testing	  ............................................................................................................................	  41	  
Image	  Acquisition	  ....................................................................................................................................................................	  42	  
Experimental	  Protocol	  ...........................................................................................................................................................	  42	  
Statistical	  Methods	  ..................................................................................................................................................................	  43	  
fMRI	  Analysis	  ..............................................................................................................................................................................	  44	  
 xii 
RESULTS	  .........................................................................................................................................................................................	  45	  
Psychophysical	  Results	  ...........................................................................................................................................................	  45	  
Regional	  Brain	  Activation	  During	  Control	  Trials	  ......................................................................................................	  47	  
Regional	  Brain	  Activation	  During	  Placebo	  Trials	  ......................................................................................................	  51	  DISCUSSION	  ...................................................................................................................................................................................	  57	  
Placebo	  antitussive	  suppression	  of	  the	  urge-­‐to-­‐cough	  ............................................................................................	  58	  
Regional	  brain	  responses	  during	  capsaicin	  inhalation	  and	  the	  effect	  of	  placebo	  .......................................	  60	  
Concluding	  Remarks	  ...............................................................................................................................................................	  62	  
CHAPTER	  5	  -­‐	  BRAINSTEM	  ACTIVITY	  ASSOCIATED	  WITH	  PLACEBO	  SUPPRESSION	  OF	  THE	  URGE-­‐
TO-­‐COUGH	  .................................................................................................................................................................	  63	  INTRODUCTION	  .............................................................................................................................................................................	  63	  METHODS	  .......................................................................................................................................................................................	  65	  
Participants	  ................................................................................................................................................................................	  65	  
Capsaicin	  threshold	  testing	  ..................................................................................................................................................	  66	  
Image	  Acquisition	  ....................................................................................................................................................................	  66	  
Conditioning	  ...............................................................................................................................................................................	  66	  
Identification	  of	  Brainstem	  Regions	  Involved	  in	  the	  Placebo	  Effect	  on	  Urge-­‐to-­‐Cough	  ............................	  66	  
Statistical	  Analysis	  ...................................................................................................................................................................	  67	  
Registration	  ................................................................................................................................................................................	  67	  
General	  Linear	  Modelling	  .....................................................................................................................................................	  67	  RESULTS	  .........................................................................................................................................................................................	  68	  
Psychophysical	  Results	  ...........................................................................................................................................................	  68	  
Confirmation	  of	  Placebo	  Related	  Changes	  in	  Activation	  in	  Expected	  Cortical	  Regions	  ............................	  70	  
Decreased	  Brainstem	  Activation	  During	  Capsaicin	  Inhalation	  Following	  Placebo	  ....................................	  71	  
Correlation	  of	  Regional	  Placebo-­‐Induced	  Signal	  Reduction	  with	  Behavioural	  Measures	  .......................	  72	  DISCUSSION	  ...................................................................................................................................................................................	  75	  
Summary	  ......................................................................................................................................................................................	  75	  
Placebo	  Suppression	  of	  the	  Urge-­‐to-­‐Cough	  ...................................................................................................................	  75	  
Brainstem	  Activity	  Associated	  with	  Placebo	  Suppression	  of	  the	  Urge-­‐to-­‐Cough	  .........................................	  76	  
Similarity	  to	  Placebo	  Analgesia	  .........................................................................................................................................	  76	  
Conclusions	  .................................................................................................................................................................................	  77	  
CHAPTER	  6	  -­‐	  CONCLUSION	  ...................................................................................................................................	  78	  SUMMARY	  OF	  FINDINGS	  ..............................................................................................................................................................	  78	  EXPERIMENTALLY	  INDUCED	  PLACEBO	  EFFECT	  IN	  URGE-­‐TO-­‐COUGH	  ................................................................................	  78	  REGIONAL	  CORTICAL	  ACTIVATION	  ASSOCIATED	  WITH	  PLACEBO	  EFFECT	  IN	  URGE-­‐TO-­‐COUGH	  ..................................	  79	  BRAINSTEM	  ACTIVATION	  ASSOCIATED	  WITH	  PLACEBO	  INHIBITION	  OF	  URGE-­‐TO-­‐COUGH	  ...........................................	  79	  IMPLICATIONS	  OF	  STUDIES	  .........................................................................................................................................................	  79	  
 xiii 
LIMITATIONS	  OF	  EXPERIMENTAL	  METHODS	  AND	  FUTURE	  DIRECTIONS	  FOR	  RESEARCH	  ..............................................	  80	  CONCLUSIONS	  ................................................................................................................................................................................	  81	  
REFERENCES	  .............................................................................................................................................................	  82	  
APPENDICES	  .............................................................................................................................................................	  96	  APPENDIX	  A	  ..................................................................................................................................................................................	  96	  
Information	  Leaflet	  .................................................................................................................................................................	  96	  APPENDIX	  B	  ...................................................................................................................................................................................	  99	  
Pre	  Scan	  Questionnaire	  .........................................................................................................................................................	  99	  
Post	  Debriefing	  Questionnaire	  .........................................................................................................................................	  100	  
 
 
 
 xiv 
List of Figures 
 
 
Figure	  1	  -­‐	  Activations	  associated	  with	  inhalation	  of	  capsaicin	   _________________________________________________________	   10	  
Figure	  2	  -­‐	  Functional	  Brain	  Maps	  of	  Sensorimotor	  Activations	  Following	  Capsaicin	  Inhalation	  in	  Humans	  _________	   28	  
Figure	  3	  -­‐	  Regions	  Consistently	  Showing	  Greater	  Activation	  in	  fMRI	  Placebo	  Analgesia	  Studies	  _____________________	   13	  
Figure	  4	  -­‐	  Effect	  of	  Placebo	  Treatment	  on	  Mean	  Capsaicin-­‐Induced	  Urge-­‐to-­‐Cough	  Ratings	  during	  Pilot	  Study	  ____	   20	  
Figure	  5	  -­‐	  Field	  of	  View	  for	  Brainstem	  fMRI	  Study	  _______________________________________________________________________	   41	  
Figure	  6	  -­‐	  Effect	  of	  Placebo	  Treatment	  on	  Mean	  Capsaicin-­‐Induced	  Urge-­‐to-­‐Cough	  Rating	  __________________________	   50	  
Figure	  7	  -­‐	  Effect	  of	  Placebo	  Treatment	  on	  Individual	  Urge-­‐to-­‐Cough	  Ratings	  _________________________________________	   34	  
Figure	  8	  -­‐	  Effect	  of	  Inhaler	  without	  Expectation	  on	  Capsaicin-­‐Induced	  Urge-­‐to-­‐Cough	  _______________________________	   35	  
Figure	  9	  -­‐	  Experimental	  Design	  ___________________________________________________________________________________________	   61	  
Figure	  10	  –	  Urge-­‐to-­‐Cough	  Ratings	  During	  Control	  and	  Placebo	  _______________________________________________________	   45	  
Figure	  11	  –	  Regional	  Decreases	  in	  Brain	  Activation	  Following	  Placebo	  ________________________________________________	   54	  
Figure	  12	  -­‐	  Regional	  Increases	  in	  Brain	  Activation	  Following	  Placebo	  and	  Correlations	  with	  Behavioural	  Measures
	  ______________________________________________________________________________________________________________________________	   74	  
Figure	  13	  -­‐	  Capsaicin	  Related	  Brainstem	  Activation	  Following	  Placebo	  and	  Control	   _________________________________	   71	  
Figure	  14	  –	  Regional	  Decreases	  in	  Brainstem	  Activation	  Following	  Placebo	  __________________________________________	   72	  
Figure	  15	  -­‐	  Regions	  where	  Decreased	  Activation	  following	  Placebo	  is	  Correlated	  with	  Behavioural	  Ratings	  ________	   74	  
 xv 
List of Tables 
 
 
Table	  1	  -­‐	  Individual	  Capsaicin	  Sensitivity	  Thresholds	  ___________________________________________________________________	   32	  
Table	  2	  -­‐	  Individual	  Capsaicin	  Doses	  _____________________________________________________________________________________	   46	  
Table	  3	  -­‐	  Regional	  Brain	  Activations	  for	  Contrast	  Control	  >	  Baseline	  __________________________________________________	   47	  
Table	  4	  -­‐	  Regional	  Subcortical	  Cerebellar	  and	  Brainstem	  Activations	  for	  Contrast	  Control	  >	  Baseline	  ______________	   50	  
Table	  5	  -­‐	  Regional	  Brain	  Activations	  for	  Contrast	  Placebo	  >	  Baseline	  __________________________________________________	   51	  
Table	  6	  -­‐	  Regional	  Brain	  Activations	  for	  Contrast	  Control	  >	  Placebo	  ___________________________________________________	   53	  
Table	  7	  -­‐	  Regional	  Brain	  Activations	  for	  Contrast	  Placebo	  >	  Control	  ___________________________________________________	   55	  
Table	  8	  -­‐	  Individual	  Capsaicin	  Doses	  _____________________________________________________________________________________	   69	  
Table	  9	  -­‐	  Regional	  Brain	  Activations	  for	  Contrast	  Control	  >	  Placebo	  ___________________________________________________	   70	  
Table	  10	  –	  Brainstem	  Activations	  for	  Contrast	  Control	  >	  Placebo	  ______________________________________________________	   73	  
 xvi 
List of Abbreviations 
 
ACC  Anterior Cingulate Cortex 
ANOVA Analysis of Variance 
BA  Brodmann Area 
BBR  Boundary Based Registration 
BOLD  Blood Oxygenation Level Dependant 
C2  Lowest dose of capsaicin to elicit 2 or more coughs  
C5  Lowest dose of capsaicin to elicit 5 or more coughs 
CBF   Cerebral Blood Flow 
CNS  Central Nervous System 
COPD  Chronic Obstructive Pulmonary Disease 
Cu  Lowest dose of capsaicin to elicit an urge-to-cough  
deHgB  Deoxygenated Haemoglobin 
DLPFC Dorsolateral Prefrontal Cortex 
EPI  Echo-Planar Imaging 
fMRI   Functional Magnetic Resonance Imaging 
FOV  Field of View 
FWE  Family Wise Error 
HgB  Haemoglobin 
HRF  Haemodynamic Response Function 
INS  Insula 
IPL  Inferior Parietal Lobe 
MEG  Magnetoencephalography 
MFG  Middle Frontal Gyrus 
MI  Primary Motor Cortex 
MNI152 Montreal Neuroscience Institute standard brain template 
MPFC  Medial Prefrontal Cortex 
MRI  Magnetic Resonance Imaging 
nTS  Nucleus of the Solitary Tract (Nucleus Tractus Solitarius) 
OFC  Orbitofrontal Cortex 
PAG  Periaqueductal Grey 
PET  Positron Emission Tomography 
PFC  Prefrontal Cortex 
PgACC Pregenual Anterior Cingulate Cortex 
 xvii 
PPC  Posterior Parietal Cortex 
PreC  Precentral Gyrus 
rACC  Rostral Anterior Cingulate Cortex 
rCBF  Regional Cerebral Blood Flow 
SI  Primary Sensory Cortex 
SII  Secondary Sensory Cortex   
SMA   Supplementary Motor Cortex 
TE  Echo Time 
TMS  Transcranial Magnetic Stimulation   
TR  Repetition Time 
 1 
Chapter 1 - Introduction 
Cough 
The cough reflex is a vital protective mechanism for clearing the airways of foreign matter such as 
aspirates, secretions, inhaled particulates, irritants or pathogens. A properly functioning cough 
reflex is essential to prevent airway damage and maintain normal airway function. There is 
however, much more to cough than the stereotypical motor response itself. Recent research has also 
begun to focus on the sensory aspects of cough, with the aim of understanding how this information 
is integrated in the central nervous system in both normal and pathological states. 
 
In the simplest case, airway afferent neurons detect physical changes in the airways and this 
information is relayed to regions of the brainstem, initiating reflexive coughing. This motor act of 
coughing is a stereotypical expulsive reflex designed to clear material from the airways. It is 
classically defined based on three characteristic phases: an initial inspiration, followed by 
compression and expulsion. Given that the cough reflex is critical to respiration, this system is 
normally tightly regulated and can be observed even in decerebate animals (Satoh, Shiba, 
Kobayashi, Nakajima, & Konno, 1998).  
 
A number of factors however, differentiate cough from other respiratory reflexes. Cough can be not 
only reflexive, but also voluntary or behavioural. It is well known that, in humans, cough can be 
voluntarily inhibited or initiated under the right circumstances, such as consciously suppressing 
cough during a concert, or voluntarily coughing on demand. In addition, cough can be modified or 
suppressed by internal factors such as attention (Van den Bergh, Vranken, Dhooge, Silva, & 
Dupont, 2011) and anxiety (Davenport, Vovk, Duke, Bolser, & Robertson, 2009; Lavorini et al., 
2010), or external factors such as social context (Van den Bergh, Van Diest, Dupont, & Davenport, 
2012). This implies that in addition to a brainstem mediated reflex loop, there must also be 
descending input from the cortex.  This level of voluntary control is unusual for a respiratory reflex, 
leading to the current interest in central nervous system mechanisms involved in generating and 
maintaining cough. 
 
Despite advances in understanding the basic physiology of reflex cough, particularly from animal 
models, there remains a lack of knowledge of how the cough sensory system is organised in 
humans. Given the lack of effective antitussive (cough suppressant) treatments currently available, 
there is a pressing need for research in this area. 
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Clinical Conditions Involving Abnormal Cough 
Complications often arise when the urge-to-cough becomes sensitised or desensitised, leading to 
constant unrelieved urge-to-cough, excessive reflex coughing or, in the case of desensitisation, a 
loss of awareness of airway function and ineffective coughing. Acute cough associated with viral or 
bacterial infection generally resolves itself with minimal complications. Chronic cough however 
has proved difficult to treat and therefore is often poorly managed, with severe consequences for 
patients’ quality of life (French, Irwin, Curley, & Krikorian, 1998). Epidemiological studies 
estimate the rate of chronic cough (defined as a cough lasting more than 8 weeks) in developed 
countries at between 9 and 33% of the adult population (Chung & Pavord, 2008), while an 
abnormal or persistent cough is among the most common reason for seeking medical treatment 
(McGarvey & Morice, 2006), being the primary reason for over 30 million visits to primary care 
providers in the United States annually ("National Ambulatory Medical Care Survey: 2010 
Summary Tables "). It is therefore surprising that so few effective antitussive treatments are 
available, and there is an increasing awareness of the need for new therapeutic tools (Bolser, 2006; 
Irwin et al., 2006). 
 
Antitussive Medications 
The most commonly prescribed antitussive treatments are codeine and dextromethorphan, both of 
which act on the central nervous system. A number of recent double blind, placebo-controlled 
studies have shown that codeine is not significantly more effective than placebo in suppressing 
cough due to upper airway disorders (Bolser & Davenport, 2007; Eccles, Morris, & Jawad, 1992). 
The efficacy of dextromethorphan has also been questioned following clinical trials showing no 
effect over placebo (Korppi, Laurikainen, Pietikäinen, & Silvasti, 1991; Paul et al., 2004; Taylor, 
Novack, Almquist, & Rogers, 1993) in treating cough due to upper respiratory tract infections, 
particularly in children. A meta-analysis of 25 randomised, placebo-controlled studies of various 
over the counter antitussives in adults and children concluded “there is no good evidence for or 
against the effectiveness of over the counter medicines in acute cough” (Smith, Schroeder, & 
Fahey, 2008). 
 
Chronic Cough Disorders 
Chronic cough and persistent urge-to-cough are associated with a variety of common medical 
conditions, among them asthma, bronchitis, chronic obstructive pulmonary disease and gastro-
oesophageal reflux (Morice, 2008). Chronic cough can also be invoked by environmental factors, 
such as smoking or pollution, sensitisation following a respiratory infection or by drug treatment 
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(particularly angiotensin-converting enzyme inhibitors) (Dicpinigaitis, 2006). Conversely, an 
impaired cough reflex is a potentially severe symptom of neurological disorders such as Parkinson's 
disease (Ebihara et al., 2003; Fontana, Pantaleo, Lavorini, Benvenuti, & Gangemi, 1998), stroke 
(Horner & Massey, 1988; Ward et al., 2010), spinal cord or traumatic brain injury (Mansel & 
Norman, 1990; Wiercisiewski & McDeavitt, 1998) and other neuromuscular disorders (Hadjikoutis, 
Eccles, & Wiles, 2000; Mutluay, Gurses, & Saip, 2005; Szeinberg et al., 1988). Unlike acute 
infections, which are generally self-limiting, many of these conditions are life long and without 
specific treatments. Therapy therefore consists of symptom management, and chronic cough has 
proven to be a particularly difficult symptom to manage effectively (Dicpinigaitis, 2011; Morice & 
McGarvey, 2009).  
 
Superficially, chronic coughing may appear to be a relatively innocuous complaint. However, 
coughing often causes secondary complications, including urinary incontinence, vomiting, rib 
fractures and loss of sleep. Perhaps most importantly from a clinical perspective, chronic cough 
leads to anxiety, social isolation and embarrassment, significantly impacting on quality of life 
(Chung & Pavord, 2008). Chronic cough patients have significantly higher rates of depression and 
anxiety than the general population (Dicpinigaitis, Tso, & Banauch, 2006; McGarvey et al., 2006), 
with reported rates of depressive symptoms comparable to those seen in patients with chronic heart 
failure and diabetes (Dicpinigaitis et al., 2006).   
 
Idiopathic Cough 
In a proportion of patients reporting chronic cough, the aetiology remains unexplained even after 
extensive clinical work-ups. It appears that in at least some of these patients a chronic unresolved 
cough may be due to an abnormal or overly sensitised cough reflex, rather than a direct result of an 
underlying condition (O'Neill, McMahon, & Undem, 2013; Pavord & Chung, 2008; Woodcock, 
Young, & Smith, 2010). It is now thought that neuronal plasticity may cause a remodelling of the 
cough reflex regulatory network following the initial infection or disease, analogous to the central 
sensitisation that is thought to occur in chronic neuropathic pain (O'Neill et al., 2013). This can lead 
to a heightened response to normally innocuous stimuli. However, as most of the current research 
into cough neurophysiology comes from animal models, the precise pathways and mechanisms that 
might be involved in this process in humans are still unexplained. 
 
Over the counter treatments such as dextromethorphan are usually ineffective in this group of 
patients (Bolser, 2006), and habituation often occurs with long term administration of opioid based 
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cough suppressants, as well as the risk of side effects (Iyer & Lim, 2013). As traditional treatments 
tend to be ineffective in this disorder, it is hoped that knowledge of the central pathways involved in 
sensing and inhibiting the urge-to-cough may be of use firstly in understanding what causes cough 
reflex hypersensitivity, and secondly in identifying prospective therapeutic targets. It is possible 
that either pharmaceutical or behavioural modification to enhance or restore the function of 
inhibitory circuits could lead to more effective outcomes than currently available treatment options. 
 
The Urge-to-Cough 
The physical discomfort caused by clinical cough is not limited to the excessive motor act of 
coughing. Often the primary complaint is rather a constant sense of irritation that is not relived by 
physical coughing. Cough is generally preceded by this sensation of irritation, usually identified as 
a feeling of an itch or tickle in the back of the throat. This is defined as the urge-to-cough, 
preceding cough similar to the way in which a sensation of itch leads to a conscious drive to 
scratch.  
 
Cough can either be generated reflexively, before a sensation of urge-to-cough is felt, or it can be 
produced via a conscious sensory process, where stimulation of the airways causes recognition of a 
desire to cough, depending on both stimulus intensity and context. In this case, the eventual 
production of cough relies on a complex chain of events, beginning with sensory input from the 
airways being passed to subcortical nuclei, before being relayed to the cortex where cognitive, 
emotional and contextual information is integrated. Descending pathways then feed back to 
brainstem regions that initiate or suppress the motor response. 
 
Studying this sensory experience of urge-to-cough, rather than the cough reflex itself, is likely to be 
more useful in terms of understanding pathological cough disorders. Additionally, understanding 
how sensory signals from the airways are processed in the central nervous system may be a more 
productive research strategy for developing antitussive therapies, as disrupting the protective cough 
reflex is not a clinically desirable aim. 
 
Modulation of the Urge-to-Cough 
Like cough, the urge-to-cough is modifiable by both internal states and external influences. If we 
are to fully understand the central nervous system changes underlying cough disorders then 
knowledge of the sensory pathways that give rise to an urge-to-cough is an important first step. 
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The urge-to-cough can be modified by anxiety (Davenport et al., 2009), exercise (Lavorini et al., 
2010) or upper airway respiratory infections (Dicpinigaitis, Bhat, Rhoton, Tibb, & Negassa, 2011). 
This strongly implies the existence of endogenous mechanisms for modulating the urge-to-cough, 
most likely involving inhibitory mediators in the central nervous system. If these inhibitory regions 
can be identified, the potential exists for them to be utilised as novel prospective targets for drug 
development. 
 
Placebo Modulation of Urge-to-Cough 
Reports of high rates of placebo responses in antitussive trials also support the supposition that 
urge-to-cough can be endogenously modulated. The placebo effect has been successfully used to 
manipulate the sensory experience of interoceptive states such as pain, and the possibility exists for 
its use as an investigative tool to better understand which brain regions are involved in modulation 
of the urge-to-cough. 
 
There has been growing interest surrounding placebo effects since Beecher reported in 1955 that 
35% of patients responded positively to placebo treatment (Beecher, 1955), leading to the 
widespread adoption of randomised placebo controlled clinical trials. Placebo effects have since 
been reported in numerous conditions, from pain to psychological disorders such as depression 
(Leuchter, Cook, Witte, Morgan, & Abrams, 2002; Walsh, Seidman, Sysko, & Gould, 2002) and 
neurological disorders such as Parkinson’s disease (de la Fuente-Fernández et al., 2001; Lidstone, 
Schulzer, Dinelle, & et al., 2010). Clinically, debate is ongoing about whether attempts should be 
made to harness this effect for therapeutic benefit, or whether the use of deception is unethical 
(Brody, 1982; Miller & Colloca, 2009; Price, Finniss, & Benedetti, 2008).  
 
Experimentally, the placebo effect has proven useful as a method of modifying the subjective 
experience of a stimulus, allowing for the study of inhibitory processes within the central nervous 
system. If placebo effects can be induced experimentally in a model of cough, this would then allow 
us to investigate the functional neuroanatomical regions involved in modifying the urge-to-cough. 
 
Placebo Effects in Cough 
It has been estimated that up to 85% of the treatment efficacy of over-the-counter anti tussive 
medications in clinical trials is due to placebo effect (Eccles, 2010). However, since these clinical 
trials do not routinely include a no treatment arm, it is unclear what factors contribute to this effect. 
Any observed response may be due to a variety of reasons, such as regression to the mean (the fact 
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that people tend to enrol in clinical trials when their symptoms are at their worst), natural resolution 
of symptoms, or the effect of substances other than the active pharmaceutical, all of which make up 
the perceived placebo effect. Regardless of the relative contributions of these factors, the magnitude 
and consistency of placebo effects reported in studies of antitussives is larger than that seen in 
studies of similar sensory processes such as placebo analgesia (Hróbjartsson & Gøtzsche, 2004a; 
Vase, Riley, & Price, 2002). 
 
The large improvements in symptoms with placebo seen in clinical trials of new antitussives could 
be one of the reasons that so few new drugs have been approved for the treatment of cough. It has 
been speculated that these effects may mask any true responses, leading to premature rejection of 
antitussives that may eventually have proved clinically useful. Investigating this experimentally in 
healthy subjects allows us to control for these factors and estimate the magnitude to which the 
“true” placebo effect might contribute to these responses. 
 
Placebo Effects in Pain 
Placebo responses can be utilised as a method of manipulating the experience of a given stimuli. 
This has been most commonly studied in relation to analgesia, in order to investigate the functional 
roles played by various cortical regions involved in pain perception. This research has proved that 
placebo analgesic responses are not only due to response bias, as was previously speculated (Price 
et al., 2008). Sensory areas in the cortex show significantly lower levels of activation when a 
subject receives a placebo treatment prior to painful stimulation, indicating that subjects are not 
merely retrospectively labelling their pain levels as less intense (Wager et al., 2004). High 
resolution imaging of the spinal cord during a placebo analgesia paradigm has further shown that 
there is reduced neural activity during pain processing even at the level of spinal cord neurons 
(Eippert, Finsterbusch, Bingel, & Buchel, 2009b), indicating a potential mechanism of placebo 
analgesia whereby descending modulation could cause inhibition of incoming sensory signals. 
 
Models of Placebo Effect 
Whilst the precise neurobiological mechanisms of placebo are still speculative, much progress has 
been made towards defining precisely what the placebo effect is, and how the brain might 
orchestrate it. Placebo effects have been primarily studied in relation to nociception, or the 
perception of pain. Other sensory systems are equally likely to be affected, such as the perception of 
tactile stimuli (Fiorio et al., 2012). 
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From a traditional point of view, the placebo effect is considered to be a learning process mediated 
by a combination of expectation and classical conditioning. Expectation can be elicited by verbal 
reinforcement, for instance: “this treatment will reduce your urge to cough”. Conditioning, in 
experimental studies, consists of a period where the level of stimulus is lowered without the 
subject’s knowledge to produce an association between the placebo and the desired outcome. In a 
clinical setting this necessarily becomes much more complex, as factors such as attitude, anxiety, 
past experience of effective or ineffective therapies and the relationship between patient and 
practitioner all contribute towards expectation, and the past experiences of the patient can 
themselves be considered a form of conditioning (Voudouris, Peck, & Coleman, 1985). This may 
contribute to the difficulties seen in treating chronic cough patients, who have usually been exposed 
to numerous ineffective treatments and therefore may have low expectations of positive treatment 
outcomes. 
 
Conditioning can also be pharmacological, where placebo replaces an active treatment after a 
period of time. This has proven effective with a range of treatments, where drug specific effects 
persist even when placebo is given. For example, after opioid treatment pain is reduced with 
placebo alone (Amanzio & Benedetti, 1999), while following treatment with an 
immunosuppressant, production of immunomodulatory cytokines is inhibited (Ober et al., 2012). 
After analgesic treatment with buprenorphine, placebo produces respiratory depression, mimicking 
the side effects of opioid treatment (Benedetti, Amanzio, Baldi, Casadio, & Maggi, 1999). 
Similarly, placebo treatment causes a naloxone-reversible reduction in heart rate (Pollo, Vighetti, 
Rainero, & Benedetti, 2003). Placebo effects can also be induced simply by observing another 
person responding positively to an analgesic (Colloca & Benedetti, 2009). 
 
It is thus clear that the “placebo effect” is not a singular entity, but must rather be regarded as a set 
of processes particular to the system being studied. As yet, despite much speculation, the underlying 
mechanisms involved in placebo effects in relation to cough have not been studied experimentally.  
 
Models of Urge-to-Cough 
The afferent pathway leading to a sensation of urge-to-cough is initiated by peripheral nerve 
receptors in the respiratory tract, particularly in the larynx, trachea and bronchi. Subpopulations of 
sensory neurons may be activated by either mechanical or chemical stimulation. Mechanical cough 
receptors in the lining of the epithelia react to physical stimulation, such as particulate matter, while 
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chemical receptors can be activated by a range of substances, including capsaicin (Hansson, 
Wollmer, Dahlback, & Karlsson, 1992; Widdicombe, 1995). 
 
These vagal afferent nerves project from the airways to the brainstem, where they appear to 
converge primarily in the nucleus of the solitary tract (nTS). The nTS is an important site for 
integration of visceral sensory information, receiving and integrating afferent input from the 
gastrointestinal system, lungs, heart and airways (Boscan, Pickering, & Paton, 2002; Broussard & 
Altschuler, 2000; Kubin, Alheid, Zuperku, & McCrimmon, 2006). Central projections both inward 
and outward from the nTS are likely to play a role in modifying the urge-to-cough sensation. 
The nTS has projections to other brainstem nuclei including the reticular formation in the medulla 
and the parabrachial complex, particularly the Kolliker-Fuse nucleus (Torvik, 1956), as well as 
subcortical projections to the hypothalamus, thalamus and amygdala (Canning, 2007; Mazzone & 
Canning, 2002; Ohi, Yamazaki, Takeda, & Haji, 2005). As well as serving as the primary relay 
nucleus, there is evidence that some degree of integration of peripheral cough sensory information 
may also occur at the level of the nTS (Bolser & Davenport, 2002; Ohi et al., 2005). 
 
Although tracing studies in animal models (primarily guinea pigs), have been invaluable in 
discovering the projections of subpopulations of sensory neurons arising from the airways, it is 
unclear to what extent these results translate to humans. Interest has thus turned towards non-
invasive tools such as functional magnetic resonance imaging (fMRI) in order to establish whether 
the same pathways exist in humans. 
 
Cortical Modulation of Urge-to-Cough 
Cough is generally initiated following the sensation of an urge to cough. Rather than being a simple 
brainstem mediated reflex, as was considered the case until relatively recently, it is now apparent 
that the process of sensing and acting upon an urge-to-cough is considerably more complex and 
involves a network of cortical regions. 
 
Evidence for this comes from multiple sources, including fMRI studies of cough and urge-to-cough 
(Mazzone, Cole, Ando, Egan, & Farrell, 2011; Mazzone, McLennan, McGovern, Egan, & Farrell, 
2007), the effect of stroke on reflex cough (Addington, Stephens, Widdicombe, & Rekab, 2005) 
and the ability in humans to voluntarily produce or suppress cough. 
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The model developed by Eccles (Lee, Cotterill-Jones, & Eccles, 2002) proposes that brainstem 
respiratory centres are modulated by input from the cortex. We have previously shown that evoked 
cough activates cortical as well as subcortical regions (Mazzone et al., 2013). It therefore seems 
reasonable to hypothesise that voluntary suppression of cough involves downregulation of 
respiratory centres in the pons and medulla via top down cortical inhibition. 
 
Functional Magnetic Resonance Imaging 
Functional or blood oxygenation level dependant (BOLD) MRI uses the differing magnetic 
properties of oxygenated and de-oxygenated haemoglobin in the blood to provide an endogenous 
contrast mechanism without the need for exposing subjects to ionising radiation. Because the ratio 
of oxygenated to de-oxygenated haemoglobin is closely coupled to neuronal activation (Logothetis 
& Pfeuffer, 2004), this allows us to localise functional activity in healthy awake human volunteers 
by statistically comparing signal intensity when the subject is engaged in a particular activity to 
either rest or a control task. 
 
The use of fMRI has enabled researchers to design studies which were not previously possible using 
either animal models or behavioural studies. For instance, human volunteers can report subjective 
experiences such as urge-to-cough. Recent studies using fMRI have shown that the network of 
cough related cortical areas is more extensive than was previously thought, incorporating inhibitory 
and regulatory regions (Mazzone, Cole, Ando, & Farrell, 2010).  Increased knowledge of the basic 
mechanisms of cough reflex regulation at both a brainstem and cortical level is needed in order to 
better understand how dysfunction occurs in chronic cough disorders. 
 
Functional Neuroanatomy of Cough and Urge-to-Cough 
Previous studies by our group utilising fMRI during induced cough and urge-to-cough have shown 
increased activation in a network of cortical and sub-cortical regions (Figure 1) (Mazzone et al., 
2011; Mazzone et al., 2007). These brain regions are likely to underlie the diverse processes 
involved in sensing and reacting to tussive stimuli, such as perception of intensity, localisation of 
irritation and motivation to initiate or suppress cough. By manipulating aspects of the sensory 
experience during fMRI, we have begun to ascribe functional roles to various components of the 
network. 
 
We first identified a distributed network of somatosensory, premotor, limbic and paralimbic areas 
that were activated during capsaicin induced airway irritation (Mazzone et al., 2007)(see Figure 1). 
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This network is likely to be composed of regions involved in sensing and acting upon information 
ascending from airway cough receptors, as well as cognitive and emotional processing of stimuli. 
Further research has focused on functional subdivision of this network.  By modelling the variance 
in subjective ratings compared to the variance in stimulus intensity, it was shown that discrete 
sections of this network responded in either a stimulus-dependant or ratings dependant fashion, 
implying that they may be involved in different aspects of sensory processing (Figure 2) (Farrell, 
Cole, Chiapoco, Egan, & Mazzone, 2012).  
 
Figure 1 - Activations associated with inhalation of capsaicin 
 
 
The majority of regional activations were distributed in both hemispheres, including the 
orbitofrontal cortex (A), inferior frontal gyrus (A, B), anterior insula (B, C), superior temporal 
gyrus (C), and primary motor and somatosensory cortices (D, G). Midline capsaicin activations 
included the supplementary motor area (E) and the anterior midcingulate cortex (F). The locations 
of capsaicin activations in the primary motor and somatosensory cortices were at the caudal end of 
the central sulci in both hemispheres (D), and are clearly discernable on the three-dimensional 
rendering of the left hemisphere. Slice coordinates are according to the Montreal Neurological 
Institute (MNI) 152 brain and activations are rendered on the average of subjects' anatomical 
images after registration to the MNI brain. Reprinted with permission from (Mazzone et al., 2007). 
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(A) Capsaicin inhalation is associated with the 
activation of a distributed network in the brain 
(Mazzone et al., 2007). We propose that this 
network is composed of several sub-circuits 
(modules) involved in sensory discrimination and 
motor control (panels B-E). Our published data 
indicate that discrete regional responses 
incorporate modules that (B) encode stimulus 
intensity, (C) identify stimulus location, (D) 
determine perceptual experiences and (E) can 
suppress evoked motor responses; see (Farrell et 
al., 2012; Mazzone et al., 2011). The module 
specific activations shown in green, pink, blue and 
yellow on panels B-E are superimposed on the 
distributed capsaicin inhalation network (shaded 
orange) as highlighted in panel A. See cited 
references for full details of experimental design, 
data analysis and interpretation. Reprinted with 
permission from (Mazzone et al., 2013). 
 
 
 
Figure 2 - Functional Brain Maps of Sensorimotor Activations Following Capsaicin 
Inhalation in Humans  
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Functional Neuroanatomy of Placebo Effect 
Most research thus far has focused on placebo effects in relation to pain and analgesia, as this is a 
relatively simple system to study experimentally. Prior to the advent of neuroimaging techniques, 
placebo effects were often explained as a result of ratings bias, where participants either 
retrospectively labelled their experience as less intense, or subconsciously adjusted their ratings in 
line with the expectations of researchers (Hróbjartsson & Gøtzsche, 2001; Hróbjartsson, Kaptchuk, 
& Miller, 2011).  
 
The first evidence for placebo as a process with a distinct neurobiological basis rather than as a 
purely psychological process came from the finding that placebo analgesia could be blocked by 
naloxone, an opioid antagonist, indicating that endogenous opioids were involved in producing 
placebo effects in pain (Levine, Gordon, & Fields, 1978). It has since been shown that while 
placebo responses following both expectation and conditioning with morphine were completely 
blocked by naloxone, conditioning using a non-opioid analgesic was not (Guo, Wang, & Luo, 
2010). It is now accepted that both opioidergic and dopaminergic pathways are involved in the 
placebo analgesia response (Scott et al., 2008). Whether this is true of placebo effects in other 
sensory systems is not yet known. 
 
Positron emission tomography (PET) studies of placebo effects in analgesia enabled localisation of 
brain regions involved in the response to placebo, including those specific to various ligands. 
Wager et al showed that during heat pain following either placebo analgesia or no treatment, 
regional µ-opioid receptor binding was enhanced in the placebo condition in a number of key brain 
regions including dorsolateral prefrontal cortex (DLPFC), anterior insula, rostral anterior cingulate 
cortex (rACC), pregenual anterior cingulate cortex (pgACC), periaqueductal grey (PAG), 
amygdala, thalamus, and orbitofrontal cortex (Wager, Scott, & Zubieta, 2007). A similar study 
using a sustained pain protocol showed increased µ-opioid receptor binding in DLPFC (Brodmann 
Area 8 and 9), PgACC (BA24 and 25), anterior insular cortex and nucleus accumbens (Zubieta et 
al., 2005). Additionally, µ-opioid receptor activity in the right DLPFC was negatively correlated 
with the expectation of analgesia. 
 
Further PET studies showed increased regional cerebral blood flow (rCBF) in medial prefrontal 
cortex (MPFC)(BA9), posterior parietal cortex (PPC)(BA7) and inferior parietal lobe (IPL)(BA40) 
after placebo administration in placebo responders, but not in placebo non-responders (Nemoto, 
Nemoto, Toda, Mikuni, & Fukuyama, 2007). 
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fMRI studies of placebo analgesia have also reported decreased activation following placebo in 
cortical regions associated with pain modulation. During painful stimuli following placebo, 
participants reported less pain as well as showing decreased activitation in insula, thalamus and 
rACC (Wager et al., 2004). The decreases in behavioural pain ratings were significantly correlated 
with activity in DLPFC, OFC and rACC. fMRI studies have also consistently reported increased 
brain activation associated with placebo in regions including the lateral prefrontal cortex and OFC 
(Wager & Fields, 2013; Wager et al., 2004) (see Figure 3). 
 
The DLPFC and OFC appear to play particularly important roles in the modulation of placebo 
effects during pain. DLPFC and OFC activation is correlated with midbrain activation in the 
vicinity of PAG (Wager et al., 2004), leading to speculation that placebo may be caused by top-
down inhibitory processes originating in the prefrontal cortex. In support of this theory, placebo 
analgesia is abolished when transcranial magnetic stimulation (TMS) is used to transiently disrupt 
DLPFC functioning (Krummenacher, Candia, Folkers, Schedlowski, & Schonbachler, 2010).  
 
Figure 3 - Regions Consistently Showing Greater Activation in fMRI Placebo Analgesia 
Studies 
 
 
Adapted from (Meissner et al., 2011a). Results of placebo analgesia fMRI studies from 2004 to 
2011 showing areas reported in three or more studies to show placebo related increases in 
activation, or placebo related correlations with brain activity, during administration or 
anticipation of pain. 
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Summary 
Placebo seems to be particularly effective at reducing cough and the urge-to-cough. Although it 
seems likely that cortical modulation of the sensory pathways involved in discerning an urge-to-
cough are involved in this process, these cortical networks have only just begun to be described in 
humans and the effect of placebo on urge-to-cough has not yet been studied experimentally. 
 
If urge-to-cough can be reduced by placebo under experimental conditions, this would imply that 
reports from clinical trials of large placebo effects in antitussive trials are due to a true placebo 
effect rather than other factors. Additionally, uncovering the functional neuroanatomy underlying 
placebo downregulation of urge-to-cough may help us to understand the processes that generate 
abnormal urge-to-cough.  
 
Aims 
This project aims to investigate cortical modulation of the perception of airway irritation using 
fMRI in healthy volunteers. By manipulating the experience of urge-to-cough using a placebo 
design combined with capsaicin cough challenges; we first attempted to establish that reports of 
high levels of placebo responses in cough could be replicated experimentally. Secondly, we aimed 
to use this manipulation to identify cortical and subcortical regions that are involved in regulating 
the urge-to-cough. 
 
Experiment 1 
The first experiment consists of a psychophysical study with the aim of establishing whether it is 
possible to elicit a robust placebo response in healthy volunteers using a capsaicin model of cough. 
Our hypothesis is that sensitivity to tussive stimuli, as measured by mean urge-to-cough ratings, 
will be significantly lower when participants receive a placebo treatment prior to capsaicin 
inhalation, compared to when they receive no treatment. If this hypothesis is true, then the placebo 
effect seen in clinical trials might be caused by a decrease in urge-to-cough. 
 
Experiment 2  
The second experiment will replicate the previous study during whole brain fMRI, allowing 
identification of cortical regions of the brain that are involved in regulating aspects of the urge-to-
cough. We hypothesise that there will be a decrease in activation in somatosensory areas relating to 
incoming sensory stimuli from the airways following placebo treatment, indicating that placebo 
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indeed acts via decreasing the neural response to stimuli. We further hypothesise that other cortical 
areas, such as the dorsolateral prefrontal cortex, will show an increase in activation during the 
placebo treatment, indicating a role in inhibitory regulation of the cough pathway. We intend to 
compare these areas to those known to play a role in placebo analgesia. This will allow us to 
establish whether there is a common network of regions related to the placebo response in different 
modalities, or whether there are specific areas related to the control of cough. 
 
Experiment 3 
To further investigate this effect, during the third experiment we will use high resolution fMRI 
optimised for the brainstem to examine processing of tussive stimuli in the brainstem during 
placebo treatment. We expect to see decreased activation in brainstem areas related to respiratory 
control, such as the nucleus of the solitary tract. This will allow us to establish whether regulatory 
cortical areas identified in the previous experiment exert their effect via descending inhibitory 
modulation of brainstem regions, or whether the inhibition occurs at a purely cortical level. 
 
Significance 
The proposed research project is expected to contribute to the understanding of cortical regulation 
of the perception of airway irritation. While the basic physiology of the cough reflex has been 
extensively studied using animal models, there is still a lack of knowledge regarding the functional 
organisation of cortical and brainstem regions involved in modulation of the urge-to-cough 
network. Given the lack of effective treatments for patients presenting with chronic cough 
symptoms and evidence suggesting that dysfunction of this regulatory network may be involved, it 
is hoped that this research could lead to novel therapeutic targets for cough disorders.  
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Chapter 2 - METHODS - Experimental Design, Functional Magnetic Resonance 
Imaging and Analysis 
 
Overview of the principles of fMRI 
The advent of neuroimaging has greatly enhanced our understanding of the functional 
neuroanatomy of the brain. Using fMRI it is now possible to visualise areas of the brain that are 
active whilst a task is being performed. New methods continue to be developed which may lead to 
further advances in functional brain mapping and clinical applications.  
 
fMRI measures changes in signal intensity over time due to local fluctuations in blood flow. These 
fluctuations reflect underlying neuronal activity relating to the task being performed (Logothetis, 
2002). fMRI offers significant advances in spatial resolution compared to other neuroimaging 
techniques such as PET and magentoencencephalography (MEG) and has the benefit of not 
exposing subjects to ionising radiation, allowing for repeat scanning of healthy participants. 
 
MRI was originally used for anatomical investigations, relying on the differing magnetic properties 
of tissues to produce contrasts between structures. In 1990 a study first described the possibility of 
using blood oxygenation level as an endogenous contrast agent, based on the differing magnetic 
properties of haemoglobin (HgB) and deoxygenated haemoglobin (deHgB) (Ogawa, Lee, Kay, & 
Tank, 1990). This led to the development of blood oxygenation level dependant (BOLD) MRI, the 
basis of functional imaging. 
 
Local neuronal activity related to task performance is accompanied by an increase in blood flow, 
presumably to supply the metabolic needs of neurons and astrocytes at active synapses (Logothetis, 
2003; Logothetis & Pfeuffer, 2004). However the increase in oxygen supply exceeds the increase in 
oxygen consumption (Fox & Raichle, 1986), leading to a greater proportion of HgB to deHgB in 
active areas. deHgB interferes with the magnetic field of nearby water molecules, leading to a 
decrease in the MRI signal detected. Because HgB does not have the same properties, an increase in 
the ratio of oxygenated blood leads to an increase in signal shortly after an area has been stimulated. 
This is known as the haemodynamic response function (HRF). The HRF is coupled to neuronal 
activity (Raichle & Mintun, 2006) and consists of an initial dip in the BOLD signal, followed by a 
peak positive signal increase 5-8 seconds following the stimulus. This delay is incorporated into 
models used in processing data from fMRI studies. 
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Airway irritations:  Modelling cough versus the urge-to-cough  
Cough and the urge-to-cough can be induced experimentally in healthy subjects using chemical or 
mechanical stimuli. Inhaled tussive challenges are the most common method, using stimuli such as 
capsaicin, citric acid, hypertonic saline or fog (Dicpinigaitis, 2003, 2007). The cough induced by 
these agents is safe, transient, reproducible and dose-dependant (Dicpinigaitis & Alva, 2005).  The 
C2 threshold (dose of tussive stimuli causing 2 or more coughs) is commonly used as a measure of 
cough sensitivity. C2 thresholds have now been reported in a number of studies. Although there is a 
wide range of natural variation between individuals, C2 thresholds are on average lower in women 
(Dicpinigaitis & Rauf, 1998; Fujimura et al., 1996) and differences in C2 thresholds have been 
reported in various groups, such as smokers (Kanezaki et al., 2010; Millqvist & Bende, 2001; 
Sitkauskiene & Dicpinigaitis, 2010) and asthmatics (Jesenak et al., 2009). Although the ability of 
C2 thresholds alone to discriminate between healthy controls and chronic cough patients on an 
individual basis is poor (Nieto et al., 2003), there is evidence that successful treatment of chronic 
cough is associated with an increase in a patient’s C2 threshold (Oconnell, Thomas, Pride, & Fuller, 
1994). 
 
During inhaled tussive challenges, subjects generally report an urge-to-cough at lower 
concentrations of stimuli than that which cause coughing (Davenport, 2008; Davenport, Sapienza, 
& Bolser, 2002). The lowest dose of tussive stimuli to generate a perception of urge-to-cough (Cu) 
has been proposed as an additional measure of urge-to-cough sensitivity (Davenport et al., 2002; 
Dicpinigaitis, Rhoton, Bhat, & Negassa, 2012). Like C2, this is a reproducible measure 
(Dicpinigaitis et al., 2012) and there is a linear relationship between increasing log-transformed 
concentrations of tussive stimuli and the urge-to-cough (Davenport et al., 2002). Unlike C2, gender 
differences have not been noted (Dicpinigaitis et al., 2012; Gui et al., 2010), however Cu is 
transiently enhanced during upper respiratory tract infections in healthy non-smoking volunteers 
(Dicpinigaitis et al., 2011).  
 
Taken together, this evidence suggests that Cu and C2 are not equivocal, instead there appears to be 
a complex interaction between these two measures. Cu may in fact be a more appropriate measure 
of sensory dysfunction such as that seen in chronic cough, as C2 measures not only the urge-to-
cough, but also the ability to suppress cough. Taking these two measures together may provide a 
more nuanced measure of abnormal cough, as together they encompass both the sensory aspect and 
the motor reflex of cough. 
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Choosing a Placebo “Treatment” 
This paradigm presents certain challenges, as there is only one route of administration for tussive 
stimuli, in contrast to placebo analgesia studies where different sites on the body (for instance the 
right hand and left hand) are typically used to compare placebo to no treatment. In analogous fMRI 
placebo analgesia studies with only one administration route, such as those involving visceral 
sensations like oesophageal or rectal pain, researchers have typically separated the placebo and 
control treatments in time, with a no treatment session followed by a placebo analgesia session (Lee 
et al., 2012; Lu et al., 2010; Price, Craggs, Verne, Perlstein, & Robinson, 2007). This strategy 
however has the drawback of greatly reducing statistical power.  
 
In developing the protocol for these studies, my aim was to design a study where periods of no 
treatment and placebo could be interspersed in the same run, allowing for a more statistically 
powerful block-design fMRI study. For this reason I chose to describe the placebo as an aerosolised 
local anaesthetic, rather than a more common form of antitussive such as a cough syrup. The only 
previous study looking at placebo effects in cough informed participants they were testing the effect 
of vitamin E tablets on cough (Lee et al., 2005). Although this proved successful in evoking a 
placebo effect, I wished to use a strategy where the treatment would be viewed as plausible, short 
acting and highly effective at reducing cough, allowing for rapid switching between control and 
treatment conditions in the same fMRI run. 
 
Aerosolised lidocaine was thus chosen as the placebo “treatment” since both local anaesthetics and 
aerosolised medications are generally perceived as being effective and short lasting, with a rapid 
onset and offset. Lidocaine was also chosen as a cough treatment that participants were unlikely to 
have experienced, removing any negative expectancy due to previous exposure to over-the-counter 
antitussive medications that may not have been particularly effective. This description served the 
additional function of being a plausible antitussive, lidocaine being used clinically to inhibit cough, 
particularly during medical procedures (Trochtenberg, 1994; Truesdale & Jurdi, 2013; Udezue, 
2001), as well as being effective at reducing capsaicin-induced cough (Midgren, Hansson, Karlsson, 
Simonsson, & Persson, 1992). This was an important consideration since participants in the studies 
were drawn primarily from advertising within the University of Melbourne, and were likely to have 
access to medical databases should they choose to research the treatment after reading the 
participant information and consent form and prior to the study. Indeed, a number of the 
participants recruited were medical or dental students or graduates. This strategy was successful in 
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that all participants reported during debriefing that they believed they had received an active 
treatment during the study. 
 
Development of Study Designs 
Our group has previously developed a reliable method of delivering aerosolised capsaicin 
challenges during fMRI scanning (Mazzone et al., 2011; Mazzone et al., 2007). During the scanning 
session, participants are fitted with a facemask attached to nebulisers containing capsaicin solution. 
At specific times, capsaicin is delivered by turning on pressurised medical air to the nebulisers, 
which participants then passively inhale via the facemask. In this series of experiments, we chose to 
deliver the placebo treatment in a distinctive fashion, rather than simply delivering nebulised saline 
via the same facemask as the capsaicin, in order to accentuate the difference between placebo 
treatment and capsaicin inhalation. 
 
In the psychophysical study this was achieved by using a placebo inhaler, a replica metered dose 
asthma inhaler that delivers a single puff of pressurised gas (Implox Healthcare, Adelaide, 
Australia). Although the inert propellant gases were not expected to have any effect on urge-to-
cough, in order to confirm the fact we explicitly tested this in a separate cohort of subjects who 
completed the same study without any expectancy, i.e. with the knowledge that the inhaler did not 
contain any active medication. Results from this study are reported in Chapter 3 and confirmed our 
expectation that the placebo inhaler alone had no effect on capsaicin induced urge-to-cough. 
 
An initial pilot experiment was conducted in order to establish the feasibility of producing a placebo 
response using a capsaicin inhalation model. This study was discontinued after seven participants 
had completed the protocol, due to a lack of observable placebo effect (Figure 4). This group of 
subjects underwent conditioning, which appeared to be successful, however no steps were taken to 
enhance expectation, and a number of participants reported during debriefing being suspicious as to 
whether they were actually receiving an active treatment.  
 
 
 
 
 
 20 
Figure 4 - Effect of Placebo Treatment on Mean Capsaicin-Induced Urge-to-Cough Ratings 
during Pilot Study 
 
 
Upper panel: shows 
results from the 
conditioning phase in 
which the challenge 
concentration of 
capsaicin was deceptively 
altered without the 
participants’ knowledge 
to give the impression that 
the inhaler treatment 
produced a transient 
reduction in urge-to-
cough sensation that 
resolved over time.  
 
Lower panel: shows 
results from the testing 
experimental phase in 
which the challenge 
concentration of capsaicin 
was maintained constant 
for all challenges. Urge-
to-cough was measured on 
a modified Borg scale for 
subjective ratings 0-10 
and inhaler treatment was administered at time = 0. No significant difference in ratings between 
placebo and no treatment was observed at any of the time points (pairwise t-test, p=n.s.). Data are 
the mean +/- SE of n=7 participants. 
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Following this pilot study, we recruited a new cohort and incorporated strategies into the paradigm 
to increase participants’ expectancy and reduce the chance of them developing suspicions regarding 
the treatment. These included: showing participants an information leaflet outlining 
contraindications and possible side effects of lidocaine (see Appendix A); adding professional-
looking labelling to the placebo inhaler, including “lidocaine hyrdrochloride 4%” and “for 
practitioner use only”; explicitly informing participants that lidocaine is highly effective at reducing 
the urge to cough; and additionally informing them that the aim of the experiment was not to test 
the efficacy of lidocaine, but rather to pilot a prospective protocol for later use in a study on chronic 
cough patients.  
 
In addition, we introduced a series of questionnaires (see Appendix B) to identify whether 
participants believed the treatment was working (following conditioning) and whether they had any 
suspicions that they were not receiving an active treatment (following debriefing). After introducing 
these extra measures, a significant decrease in urge-to-cough ratings was observed in subsequent 
cohorts. Similarly, a recent study also showed increased placebo analgesia in participants who had 
received an educational handout about the treatment (Tang & Colagiuri, 2013). This observation 
underlines the importance of both conditioning and expectation in the elicitation of experimental 
placebo effects.  
 
Development of Placebo MRI protocol 
Whilst effective, this method of lidocaine administration needed to be modified for the following 
study to meet the restraints of an MRI environment. Namely, the ferromagnetic properties of the 
pressurised gas canister prohibited its use during scanning. For this reason a nasal cannula was used 
as the method of placebo delivery during the MRI studies. This allowed us to again differentiate the 
treatment from the capsaicin inhalation, while still using aerosolised lidocaine as the supposed 
treatment. 
 
This experiment required some modification of the capsaicin inhalation protocol that our group has 
previously used during MRI studies (Farrell et al., 2012; Mazzone et al., 2011; Mazzone et al., 
2007). In these studies the subject was cued 5 seconds prior to the onset of capsaicin and asked to 
time their next inhalation to coincide with the onset of capsaicin delivery. This introduced a random 
period of breath holding into most trials. Even a brief breath hold of this nature has a tendency to 
create negative signal change in the fMRI data that can persist for up to 20 seconds (Abbott, 
Opdam, Briellmann, & Jackson, 2005). Normally this would not cause significant issues as the 
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artefacts introduced are both normally distributed and present in all conditions, thereby not 
affecting the contrasts of interest e.g. between high dose and low dose capsaicin. It may however 
lead to less statistical power owing to variation in breath hold depth and length between trials.  
 
In the proposed experiment however, the nasal inhalation would have been required to precede the 
capsaicin inhalation by more than twenty seconds, or the beginning of the capsaicin inhalation 
period would be affected by this negative signal change. Introducing a twenty second baseline 
period would have reduced the number of trials able to be presented within a reasonable amount of 
time, also lowering statistical power. For this reason it was decided to trial a method where 
participants were not cued and instead were encouraged to breath normally throughout the 
experiment while their respiratory cycle was measured by way of a respiratory belt, time locked to 
both stimulus presentation and scanner acquisition. This allowed for the respiratory phase to be 
reconstructed relative to the onset and offset of stimuli, and the trial timings to be adjusted 
accordingly, without the need for breath holds. For instance, if the subject was exhaling as the 
capsaicin was turned on, timings for statistical analysis were adjusted to begin at the next 
inhalation. This was achieved using LabChart (ADInstruments; http://www.adinstruments.com/) 
and custom Python scripts (http://www.python.org/). 
 
Respiratory related global signal decreases were still observed in the data using this method, likely 
due to the change in respiratory pattern from normal breathing to nasal breathing, however they 
were of a lesser magnitude than that observed previously using cued inhalation and, most 
importantly, they did not differ between control and placebo conditions. As the task is intrinsically 
linked to respiration, these artefacts are difficult to avoid and additional analysis steps were 
incorporated in order to minimise their effect. 
 
To account for the residual respiratory noise, additional regressors were incorporated into the 
general linear model as advocated by Birn et al and successfully implemented in previous studies 
(Birn, Murphy, Handwerker, & Bandettini, 2009; Farrell et al., 2012; Mazzone et al., 2011). In the 
whole brain MRI study these included regressors from cerebrospinal fluid (CSF), white matter and 
voxels with high standard deviation in the sagittal sinus. Signals from these regions reflect 
physiological noise associated with cardiac and respiratory cycles and would not be expected to 
show task related changes. This has proven to be equally or more effective than methods such as 
utilising physiological measurements, such as RETROICOR (Glover, Li, & Ress, 2000). As the 
haemodynamic response function peaks at roughly 6 seconds post stimulus and the effect of 
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respiration on the signal peaks up to 20 seconds post stimulus, the loss of power from regressing out 
possibly task correlated respiratory changes should be minimal.  
 
In the whole brain MRI study (Chapter 4) an additional regressor was created to account for these 
global effects (Andersson, 1997). As the brainstem is less susceptible to low frequency global 
artefacts, this step was not included in the brainstem analysis (Chapter 5). For the brainstem 
analysis, regressors were created to minimise high frequency fluctuations from cardiac and 
respiratory processes, these included time courses from voxels in CSF, voxels of highest standard 
deviation in the left and right carotid arteries, and voxels with high standard deviation in the sagittal 
sinus. 
 
Development of Brainstem Placebo MRI protocol 
The brainstem fMRI protocol was similar to the whole brain fMRI protocol with the following 
exceptions: participants completed three runs rather than four in order to minimise total scanning 
time; similarly, the time between the placebo presentation and capsaicin challenge was reduced, 
allowing for a greater number of challenges to be presented in the same amount of scanning time. 
The field of view (FOV) was reduced to 27 slices covering the brainstem, allowing for greater 
spatial and temporal resolution (See Figure 5). 
 
In the brainstem fMRI experiment, the addition of a line fixed to the nebulisers and connected to a 
syringe allowed for the adjustment of capsaicin doses from outside of the MRI scanner. This 
allowed doses to be adjusted as necessary (for instance if the participant became habituated to the 
stimuli or began to cough during the scan), without the need to withdraw the participant from the 
MRI scanner. This saved time during the session, as well as removing the need for extra localisation 
scans, and minimising registration issues to changes in the participant’s head position. This 
relatively simple procedure would be recommended for any future MRI studies utilising nebulised 
capsaicin. 
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Sagittal cross section showing average field of view for all participants (in blue) optimised for 
brainstem imaging, overlaid on a standard MNI template. 
 
Subcortical MRI imaging presents particular challenges due to both the scarcity of human research 
accurately localising brainstem nuclei and the higher signal variability in brainstem regions. Signal 
to noise ratios in the brainstem are lower than in the cortex due to the proximity of tissue 
boundaries which differ in their magnetic susceptibility, introducing distortions into the magnetic 
field. Temporal variation in physiological processes also increases signal variability. Cerebrospinal 
fluid flow, respiratory cycle and cardiac pulsations due to the proximity of both the trachea and 
large veins to the region of interest all contribute to image distortion and increased levels of noise in 
fMRI studies of brainstem processing (Barry et al., 2013).  
 
Additionally, registration of individual brains to a standard template, as implemented in all 
currently available fMRI analysis software, is optimised for the cortex rather than subcortical 
regions. For this reason we used a multi-stage registration process, incorporating as a first step 
registration to a whole brain EPI image at the same resolution as the functional images, before 
registration to an individual high resolution T1 image, which was in turn registered to a standard 
MNI template. This approach has been shown to improve image registration when working with a 
FOV containing limited numbers of slices (Limbrick-Oldfield et al., 2012). 
 
Although probabilistic atlases incorporating the cerebellum have recently become available 
(Diedrichsen, Balsters, Flavell, Cussans, & Ramnani, 2009; Diedrichsen et al., 2011), standardised 
Figure 5 - Field of View for Brainstem fMRI Study 
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MRI templates incorporating atlas tools are yet to be developed for regions in the medulla and pons. 
Given the recent advances in high-resolution 7T fMRI scanning and a concurrent increase in the 
number of studies looking at small brainstem or spinal cord nuclei, research into tools for 
automated registration and localisation of subcortical regions would be of great benefit for future 
research. 
 
As information regarding the potential regions involved in capsaicin-related urge-to-cough 
suppression is limited, we chose to use a relatively large region of interest based on results from the 
whole brain MRI study, rather than the alternative option of restricting analyses to a priori regions 
based on anatomy. While this may somewhat reduce statistical power, as potential regions of 
interest cannot be defined based on individual anatomy, it has the advantage of being inclusive 
(Napadow, Dhond, Kennedy, Hui, & Makris, 2006). This allows for identification of activation in 
unexpected regions, as well as being more robust with respect to individual variation in brainstem 
structure and accuracy of registration to a standard template.  
 
The region of interest was thus taken from a summary map of brainstem areas activated during any 
condition (control, placebo or conditioning) in the whole brain study. This was used in conjunction 
with FSL Randomise to produce activation maps restricted to relevant regions in the brainstem. 
This not only confined analysis to the relevant regions, but also restricted analysis to regions 
expected to show increases in activation relative to baseline, reducing the chance of spurious 
“activations” due to relative changes in deactivation. 
 
Summary 
Capsaicin inhalation challenge is a reliable method of inducing urge-to-cough in healthy volunteers. 
Expanding on our previously developed method of delivering aerosolised capsaicin during fMRI 
scanning, the following studies employ a novel method of non-cued inhalation periods. Placebo 
suppression of the capsaicin induced urge-to-cough was achieved by a combination of expectation 
and conditioning. Describing the placebo treatment as an aerosolised local anaesthetic allowed for 
alternation between placebo and no treatment trials in the same block design fMRI run, increasing 
the statistical power of the design.
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Chapter 3 - The Effect of Placebo Conditioning on Capsaicin-Evoked Urge-to-
Cough 
 
Abstract 
 
Background:  The urge to cough is a clinical symptom of respiratory disease that precedes the 
motor act of coughing. Although previous studies have shown that cough is particularly susceptible 
to placebo suppression, it is unclear whether the perception of an urge to cough is also modifiable 
by placebo. Therefore, we tested the hypothesis that capsaicin-evoked urge to cough could be 
suppressed by placebo conditioning. 
 
Methods:  Eleven healthy participants were unknowingly conditioned to believe that an inert 
inhaler temporarily suppressed capsaicin-induced urge to cough by deceptively modifying the 
challenge concentration of capsaicin. In subsequent testing, capsaicin-evoked urge-to-cough 
subjective ratings were assessed in four challenges with a single dose of inhaled capsaicin following 
no treatment or the placebo metered-dose inhaler. An additional 10 participants were informed that 
the inhaler therapy was inert prior to receiving capsaicin challenges with and without inhaler 
treatment. 
 
Results:  There was a significant decrease in mean urge-to-cough ratings to capsaicin challenge 
following placebo compared with no treatment followed by capsaicin challenge (P < .001), with a 
peak decrease of 45%. The placebo inhaler alone had no effect on urge-to-cough subjective ratings 
when participants were aware that it contained no active medication. 
 
Conclusions:  These data confirm that the urge to cough is susceptible to placebo inhibition. This 
provides further evidence that higher brain networks are involved in the processing of respiratory 
sensations related to airway irritation. 
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Introduction 
Although coughing can be initiated via a brainstem reflex independent of higher order neural 
control, this may not be the case in cough disorders in which excessive coughing, behavioural 
coughing and the persistent desire to cough (urge-to-cough) are hallmark characteristics 
(Davenport, 2009; McGarvey & Morice, 2006). Studies from our group have described higher brain 
networks involved in the sensory and motor control of cough in humans (Mazzone et al., 2011; 
Mazzone, McGovern, Koo, & Farrell, 2009; Mazzone et al., 2007). These studies highlight the 
complexity of cough neural circuitry and argue against the concept that coughing is purely a 
reflexive response to airway irritation. Consistent with this, cough is highly susceptible to placebo 
suppression. Indeed, many currently available antitussive therapies, including codeine and 
dextromethorphan, offer minimal therapeutic effect over placebo in treating cough (Eccles et al., 
1992; Lee et al., 2005; Smith, Owen, Earis, & Woodcock, 2006; Tukiainen et al., 1986). Given that 
antitussive therapies provide symptom relief, these observations suggest a high propensity of cough 
neural pathways to be regulated by higher order inhibitory control mechanisms. 
 
The mechanisms by which placebo suppresses coughing are poorly described. It has been 
speculated that antitussive medications may work either because of a true placebo effect (Eccles, 
2002) or as a consequence of non-pharmacologic agents (such as sugar) in the antitussive 
formulations, which may act to recruit endorphin or opioidergic circuitry in the brain (Fuller & 
Jackson, 1990). Regardless of the mechanism of action, placebo groups in antitussive clinical trials 
often show improvements in outcome measures above what would be expected as a result of 
spontaneous resolution of symptoms (Birring, 2009). For example, a meta analysis of antitussive 
clinical trials for upper respiratory tract infection reported a mean placebo response rate of 85% 
relative to the active medication groups (Eccles, 2002). The importance of placebo effects in 
antitussive clinical trials and the need for further research in this area has been widely noted 
(Birring, 2009; Eccles, 2002, 2010). Large placebo effects may obscure the clinical benefit of 
treatments under investigation (Temple & Ellenberg, 2000; Temple, 1997), resulting in therapies 
that appeared promising in animal experiments failing to reduce cough over placebo in clinical 
trials, even though they may be more effective than no treatment in clinical practice (Meissner, 
Kohls, & Colloca, 2011b). 
 
Although available evidence suggests that both placebo intervention and voluntary control 
mechanisms can suppress the motor act of coughing (Hutchings, Morris, Eccles, & Jawad, 1993; 
Lee et al., 2005), it is unclear if the sensory perception of airway irritation is similarly susceptible to 
higher order inhibitory control. Indeed, no studies have explicitly investigated the effects of placebo 
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on the urge-to-cough, a measure of airway sensation.  
 
The aim of the current study was therefore to determine whether placebo intervention would 
decrease the subjective sensation of airway irritation in healthy humans.  
 
Methods 
Participants 
This study was approved by the Melbourne Health Human Research Ethics Committee (approval 
number 2010-073). A total of 21 healthy adult volunteers were recruited. Participants were 
excluded from the study if they had a history of chronic respiratory disease or gastroesophageal 
reflux, or a recent history of acute respiratory infection (minimum of 6 weeks symptom free) or had 
smoked in the past 6 months. Studies of placebo responses often necessitate participant deception. 
Information and consent procedures were therefore developed in consultation with our institutional 
ethics committee with the objective of sustaining a viable experimental model while acknowledging 
concerns about informed consent. All participants gave written informed consent using a modified 
consent form, in which the general nature of all procedures and risks involved in participating in the 
study were detailed, but the aim of testing a placebo was omitted. A written and verbal debriefing 
was provided to participants at the conclusion of the experimental session to disclose the deceptive 
nature of the study and to explain in detail the true aims and methods used and the reasons for 
including deception in the study design. A second informed consent was then sought from 
participants to use their data collected during the experiment. No participant chose to exclude their 
data from the protocol. 
 
Capsaicin sensitivity testing 
This study assessed subjective reports of the urge-to-cough evoked by inhalation of capsaicin, a 
chemical that causes transient airway irritation and is widely used to investigate cough 
(Dicpinigaitis, 2007; Dicpinigaitis & Alva, 2005). Capsaicin challenges were delivered via pressure 
driven nebulisers (RapidFlo, Alkaline Corporation) connected to an air compressor (flow rate 0.42 
ml/min; Liberty Healthcare Corporation). Capsaicin concentrations were prepared in doubling doses 
from 0.25 μM (Mazzone et al., 2007), and participants were challenged with a random series of 
single vital capacity inhalations to determine their individual sensitivity. After each inhalation 
participants were asked to rate their urge-to-cough on a modified Borg scale ranging from 0 (no 
discernible urge) to 10 (maximal urge). The capsaicin concentrations that resulted in the first 
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perceivable urge-to-cough and that first evoked two or more coughs were defined as the urge-to-
cough (Cu) and cough (C2) threshold concentrations, respectively (Davenport, 2009; Dicpinigaitis 
et al., 2012).  A moderate stimulus intensity (MI) was defined as a dose of capsaicin causing an 
average urge-to-cough rating of 6. 
 
Expectation 
Participants (n = 11) were informed via a scripted dialogue that the aim of the study was to assess 
the length of time that a treatment would reduce their urge-to-cough in response to capsaicin 
challenge. Participants were told they would receive lidocaine hydrochloride, a commonly used 
local anaesthetic that would be highly effective at reducing the urge-to-cough for a short period of 
time. The placebo “lidocaine” was delivered via self-administration of one puff of a placebo 
metered dose inhaler (Implox Pty Ltd), professionally labelled as “4% lidocaine hydrochloride” but 
containing only inert propellant gases. Participants were also shown an information leaflet outlining 
possible side effects and contraindications to reinforce the deception. An inhaler was chosen as the 
placebo intervention because it was unlikely to have been encountered by healthy participants in 
this context, avoiding the possibility of negative expectations due to previous use of non-
prescription antitussives which could have reduced the effect of conditioning (Colloca & Benedetti, 
2006). Additionally, inhaled medications and local anaesthetics are often associated with a short 
duration of effect, allowing for a within subject cross-over design. 
 
Conditioning 
Participants were led to expect that the treatment would be effective but would wear off over a 
period of approximately 2 minutes. This deception was reinforced by informing participants that 
they would receive either “lidocaine”, or no treatment, followed by a series of four vital capacity 
breath MI concentration capsaicin challenges, 30 seconds apart. During no treatment trials 
participants indeed received four challenges with their individualised MI capsaicin concentration. 
However during placebo trials the capsaicin concentrations were lowered without participants’ 
knowledge to one eighth, one quarter and one half the MI dose for the first three challenges 
respectively. The fourth challenge was at the MI dose to reinforce the transient nature of the 
treatment. During conditioning, two no treatment and two placebo trials were conducted in a 
randomised order, with 1 minute intervals between trials. 
Testing 
During the testing phase, a further two placebo and two no treatment trials were conducted as 
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described previously, with the exception that the MI concentration was administered during all 
capsaicin challenges. Subjects were not aware that these trials varied from the preceding ones. 
Following the conclusion of testing, participants were asked whether they thought the treatment was 
effective. After debriefing, participants were asked if they had had any suspicions before or during 
the study that the treatment was a placebo. 
 
Effect of metered dose inhaler on urge-to-cough thresholds 
To confirm that the inert propellant gases in the metered dose inhaler did not affect capsaicin 
evoked urge-to-cough, a separate experiment was conducted in a second cohort of participants 
(n=10) who were aware that the inhaler contained inert gases but were unaware of the expected lack 
of effect of these gases on capsaicin urge-to-cough ratings. Thirty seconds after receiving either no 
treatment or the metered dose inhaler, participants were administered a single breath capsaicin 
challenge of one of three different doses. The doses presented were low (one half the MI capsaicin 
concentration), moderate (MI capsaicin concentration), or high (double the MI capsaicin 
concentration), based on each individual’s capsaicin sensitivity. Twelve randomised trials were 
presented, consisting of four instances of each dose, preceded by the metered dose inhaler on one 
half the occasions. Participants were asked to rate their urge-to-cough following each capsaicin 
challenge as described previously. 
 
Statistical Methods 
All analyses were carried out with PASW statistics (Release Version 18.0.0, SPSS, Inc., 2009, 
Chicago, IL, www.spss.com). Attributes of the sample were characterised with descriptive statistics. 
The doses required to elicit Cu, C2 and MI were tabulated for each participant and the geometric 
means were calculated by logarithmic conversions of the doses averaged across the sample. 
Multivariate comparisons were performed using repeated measures analysis of variance (ANOVA). 
Urge-to-cough ratings were averaged across trials for each challenge and condition for each 
participant and these mean ratings were used to test for the effects of conditioning (conditioning 
versus testing), treatment (placebo versus no treatment), challenge (four serial capsaicin challenges) 
and the interactions of the factors. Another ANOVA was used to assess the effects of inhaler, 
stimulus dose and their interaction on the urge-to-cough ratings of the second cohort of participants. 
Post hoc testing of paired observations was performed with dependent t-tests; p< 0.05 was 
considered significant. 
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Results 
Participants 
Eleven healthy volunteers aged between 19 and 42 were recruited for testing placebo evoked 
suppression of the urge-to-cough (age, 27.3 ± 6.9, 4 males). Ten additional volunteers (age, 31.7 ± 
9.2 years, 4 males) were recruited to test the effect of the metered dose inhaler on urge-to-cough 
ratings. 
 
Thresholds and Urge-to-Cough Ratings 
The Cu, C2 and MI thresholds and geometric means are reported for each participant in Table 1. 
Repeated measures ANOVA of urge-to-cough ratings showed significant within subject effects for 
the three main factors of conditioning (F(1,10) = 5.2, p < 0.05), treatment (F(1,10) = 102.0, p <t(10) 
= 3.2, p <0.001) and challenge (F(3,30) = 15.6, p < 0.001). Two-way interactions between the main 
factors were also significant (conditioning by treatment [F(1,10) = 8.1, p < 0.05], conditioning by 
challenge [F(3,30) = 4.8, p < 0.001], treatment by challenge [F(3,30) = 21.6, p < 0.001]), as was the 
three-way interaction (F(3,30) = 7.4, p 0.001). A tendency for urge-to-cough ratings to generally 
decrease in magnitude across the course of the experimental protocol explained in part the 
significant effects of conditioning and its interaction with the inhaler. When expressed as 
proportional effects, placebo was associated with a 37.9% decrease in urge-to-cough ratings during 
the conditioning phase and a 28.3% decrease in the testing phase.  
 
Differences in the effects of treatment between conditioning and testing during successive 
challenges accounted for the remaining two and three way interactions. The first three capsaicin 
challenges during conditioning were associated with significantly decreased ratings of the urge-to-
cough after placebo (challenge 1 t(10) = 9.9, p < 0.001, challenge 2 t(10 = 6.6, p < 0.001, challenge 
3 (t(10) = 2.7, p < 0.05; Figure 6). This is consistent with the conditioning strategy of administering 
lower capsaicin doses during the first three challenges. Successively increasing doses after placebo 
during conditioning led to graduated responses as indicated by significant pairwise increases of 
urge-to-cough ratings across the three initial challenges (challenge 1 versus 2 t(10) = 6.3, p < 0.001, 
challenge 2 versus 3 t(10) = 5.1, p < 0.001, challenge 3 versus 4 t(10) = 7.9, p < 0.001).  
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Table 1 - Individual Capsaicin Sensitivity Thresholds 
 
a One participant did not 
have a C2 event at any of the 
concentrations tested 
Abbreviations: Cu: Lowest 
concentration at which a 
noticeable perception of 
urge-to-cough was first 
recorded. MI: Concentration 
that was rated closest on 
average to 6 on the scale of 
urge-to-cough after multiple 
single breath challenges. 
C2: Lowest concentration 
which first produced 2 or 
more coughs. 
 
 
 
 
Examination of the urge-to-cough ratings of individual participants during the testing phase 
indicates that the placebo effect was more consistent during the first two challenges (Figure 7). 
Only one participant in the first challenge and two participants in the second challenge failed to 
demonstrate a lower urge-to-cough rating after placebo compared with the no treatment trials. The 
reductions in urge-to-cough ratings following placebo during the testing phase for the first two 
challenges were 44.7% and 38.7%, respectively. During the testing phase all 11 participants had a 
lower mean score for the combined challenges after placebo compared to no treatment. 
 
 
 
ID No 
Cu 
(µM) 
MI 
(µM) 
C2 
(µM) 
1 0.98 31.25 62.5 
2 0.98 7.81 7.81 
3 0.98 15.63 31.25 
4 1.95 31.25 -a 
5 0.98 3.91 0.98 
6 0.98 7.81 3.91 
7 0.98 3.91 0.98 
9 0.98 1.95 3.91 
9 1.95 31.25 31.25 
10 0.98 7.81 3.91 
11 0.98 7.81 1.95 
    
 Mean ± S.D. 1.16 ± 0.39 13.67 ± 11.82 14.85 ± 20.46 
 33 
 
Upper panel: shows results 
from the conditioning 
experimental phase in 
which the challenge 
concentration of capsaicin 
was deceptively altered 
without the participants’ 
knowledge to give the 
impression that the inhaler 
treatment produced a 
transient reduction in urge-
to-cough sensation that 
resolved over time. Lower 
panel: shows results from 
the testing experimental 
phase in which the 
challenge concentration of 
capsaicin was maintained 
constant for all challenges. 
In this panel, the successful 
demonstration of a placebo 
effect can be seen at 30, 60 
and 120 seconds after inhaler treatment. Urge-to-cough measured on a modified Borg scale for 
subjective ratings 0-10 and inhaler treatment was administered at time = 0 (see text for details). An 
overall decrease in ratings between the conditioning and testing phases was observed. Asterisks 
represent significant differences between placebo and no treatment (pairwise t-test, p<0.05). Data 
are the mean +/- SE of n=11 participants.
Figure 6 - Effect of Placebo Treatment on Mean Capsaicin-Induced 
Urge-to-Cough Rating 
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Figure 7 - Effect of Placebo Treatment on Individual Urge-to-Cough Ratings 
 
Mean urge-to-cough ratings are shown for each individual during the testing experimental phase. 
Participants (n=11) received the same capsaicin doses for each challenge following either placebo 
inhaler or no treatment at time = 0. Panels A-D show mean urge-to-cough ratings from each 
participant following capsaicin challenge at 30, 60, 90 and 120 seconds, respectively. Larger 
markers at datapoints indicate multiple subjects with the same mean rating. 
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Effect of metered dose inhaler on urge-to-cough ratings 
There was no significant difference between capsaicin evoked urge-to-cough ratings following 
inhaler versus no inhaler when subjects were aware that the inhaler did not contain any active 
medication (F(1,9) = 0.128, p=0.729). There was a significant effect of capsaicin dose (F(2,18) 
=32.35, p<0.001), but no significant interaction between dose and intervention (F(2,18)=0.27, 
p=0.766) (Figure 8).  
 
Figure 8 - Effect of Inhaler without Expectation on Capsaicin-Induced Urge-to-Cough 
 
 
 
Mean urge-to-cough ratings for individual participants (n=10) when they were aware that the 
placebo inhaler contained no active medication. Results shown are mean urge-to-cough ratings for 
low, medium and high dose capsaicin challenge following either inhaler or no treatment. There was 
no significant difference between urge-to-cough ratings following inhaler or no treatment (p=0.7). 
Larger markers at datapoints indicate multiple subjects with the same mean rating. 
 
Debriefing 
No participants reported suspicions that the treatment was inactive or did not contain lidocaine and 
none were aware prior to debriefing that the study was investigating placebo effects. All 
participants reported thinking that the treatment was effective at reducing the urge-to-cough. 
Discussion 
This study has demonstrated that conditioning and an expectation of relief are sufficient to produce 
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substantial reductions in urge-to-cough ratings. This effect was consistent, with all participants 
reporting decreased levels of the urge-to-cough in response to capsaicin challenges after inhalation 
of an inert propellant gas that was erroneously ascribed with antitussive properties. The consistency 
and magnitude of effects associated with deception in this study show that the urge-to-cough, like 
the cough motor event, is influenced by placebo. Furthermore, the findings provide additional 
support for the proposition that cough and attendant sensations are subject to modulation by 
suprapontine brain mechanisms.  
 
The urge-to-cough is a subjective experience represented in distributed brain regions that respond to 
stimulation of the airways (Mazzone et al., 2009; Mazzone et al., 2007). Our current understanding 
of the urge-to-cough is that it subserves a motivation to action function, informing the higher brain 
about the presence of irritants in the airways (Davenport, 2008). In this sense, the urge-to-cough 
may be important in the behavioural regulation of cough, which might otherwise proceed in a 
purely reflexive manner. This study shows that in addition to attentional focus, emotion and 
learning (Van den Bergh et al., 2012), participant belief in urge-to-cough suppression (i.e., placebo) 
can modulate the sensory experience. Interestingly, the magnitude of the effect seen in the current 
study is large compared with results from studies of placebo responses in other systems (Pollo, 
Carlino, & Benedetti, 2011; Price, Riley, & Vase, 2003; Vase, Petersen, Riley, & Price, 2009), 
despite the fact that habituation to the stimuli over the course of the experiment, as shown by a 
general decrease in urge-to-cough ratings over time, may have led to an underestimation of the 
effect size. This suggests that the urge-to-cough may be particularly susceptible to modulation by 
subjective belief, which is consistent with evidence from clinical trials reporting large placebo 
responses in measures of cough symptom improvement (Eccles, 2002). 
 
Although the outcomes of this study suggest that central processing of input from the airways can 
be influenced by cognitive factors, the mechanisms involved in this modulation are not known. 
Conditioning and beliefs consistent with relief from the urge-to-cough may lead to recruitment of 
neural circuits that modify the processing of airway sensations. There is a growing awareness of the 
pathways that contribute to processing of inputs from chemosensitive and mechanosensitive 
primary afferents in the airways (McGovern, Davis-Poynter, Farrell, & Mazzone, 2012) and these 
pathways could provide prospective targets for top-down modulation. Comparable studies 
investigating brain responses during noxious somatosensory stimuli using functional brain imaging 
have shown that placebo treatment not only reduces participants’ subsequent pain ratings, but also 
decreases activation in pain-related brain regions including the insula, thalamus, anterior cingulate 
and somatosensory cortices (Bingel, Lorenz, Schoell, Weiller, & Buchel, 2006; Price et al., 2007; 
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Wager et al., 2004). Thus, top-down modulation of processing of airway inputs would be analogous 
to the descending inhibitory circuits that have been implicated in placebo effects on pain reports in 
humans (Eippert et al., 2009a; Eippert et al., 2009b).  
 
Because the urge-to-cough can be a troubling symptom in its own right, top-down circuits that 
modulate the processing of airway sensory inputs would be a welcome prospect for the 
development of future therapies should such putative mechanisms find empiric support. Given the 
outcomes of this study, the combination of placebo treatment of the urge-to-cough with functional 
brain imaging in humans could provide a viable experimental approach to identify endogenous 
mechanisms for the relief of sensations arising from airway irritation.  
 
Previous studies have elegantly shown that the motor act of coughing is susceptible to conscious 
suppressive control mechanisms (Hutchings et al., 1993). Indeed, we have previously reported the 
neural networks in humans that we believe to be involved in voluntary motor suppression of cough 
(Mazzone et al., 2011). It is unclear whether the placebo evoked suppression of urge-to-cough noted 
in the current study similarly represents voluntary control of stimulus sensory perception or urge-to-
cough generation. Although previous studies of cough motor suppression have not rigorously 
reported urge-to-cough scores, we have recently shown that the urge-to-cough persists during 
voluntary suppression of cough at threshold doses of capsaicin (Farrell et al., 2012). This would 
argue against the existence of a common neural network that is responsible for motor cough 
inhibition and placebo evoked regulation of the urge-to-cough. Comparisons of the network 
components involved in these two suppressive events will help shed light on this question.  
 
It is also conceivable that non-specific factors could influence subjective reporting without 
impacting the processing of inputs from the airways. For instance, participants could appraise their 
sensory experiences depending on context so as to label their urge-to-cough as less intense when 
such a reduction was consistent with their expectations, or the expectations of the researchers. 
Anxiety may also shape responses to capsaicin challenge. Others have shown that anxiety can 
influence the experience of respiratory sensations, including the urge-to-cough (Davenport et al., 
2009; von Leupoldt, Chan, Bradley, Lang, & Davenport, 2011). The experimental protocol used in 
this study could produce systematic differences in anxiety levels if the expectation of relief after 
placebo reduced anxiety about inhaling capsaicin. Finally, it must be acknowledged that our data 
are specific to capsaicin-evoked urge-to-cough at moderate stimulus intensities. It is unclear at 
present whether our findings can be extended to other cough modalities (e.g., mechanical, citric 
acid, fog, and so forth) or to stimulus intensities beyond the moderate range.  
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Conclusions 
Placebo administration alone produced a peak 45 percent reduction in the urge-to-cough, supporting 
existing evidence that cortical brain mechanisms regulate both the sensory and the motor control of 
coughing. Understanding the neurophysiologic basis of the endogenous mechanisms of placebo 
cough suppression may lead to novel therapeutic targets for the treatment of excessive cough in 
disease.  
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Chapter 4 - Brain activity associated with placebo suppression of the urge-to-
cough in humans 
 
Abstract 
 
Rationale: Antitussive therapies are accompanied by a substantial placebo effect, indicating that 
inhibitory circuits in the brain have a significant capacity to regulate cough neural processing.  
However, essentially nothing is known about the identity of these inhibitory circuits or how they 
reduce coughing.  Understanding these processes may help develop more effective antitussive 
therapies in the future.   
 
Objectives: To identify regional changes in human brain activity related to the urge-to-cough 
following placebo antitussive administration. 
 
Methods: Seventeen healthy participants undertook functional magnetic resonance imaging while 
completing a series of inhalations of capsaicin to induce the urge-to-cough.  The resultant brain 
responses associated with capsaicin inhalation without any treatment were compared to those 
induced by capsaicin following placebo antitussive administration.  
 
Measurements and Main Results: There was a significant decrease in participants’ ratings of 
urge-to-cough following the placebo antitussive administration. Brain activity associated with 
capsaicin inhalation was less in the somatosensory, primary motor, insula and cingulate cortices 
during placebo antitussive trials compared to no treatment controls.  By contrast, placebo trials were 
associated with increased activation in the prefrontal and left parietal cortices. 
 
Conclusions: Placebo-related decreases in urge-to-cough are accompanied by commensurate 
decreases in several brain regions activated during capsaicin inhalation, suggesting that beliefs 
about treatment can modify the central processing of inputs arising from the airways. The prefrontal 
cortex and posterior parietal cortex are likely to play an active role in the modification of airway 
sensory processing after administration of a placebo. 
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Introduction  
The urge-to-cough is recognised as an important clinical symptom that accompanies chronic cough 
hypersensitivity disorders (Chung, 2011; Morice, McGarvey, & Dicpinigaitis, 2012).  It is 
characterised by sensory nerve-dependent perception of airways irritation and the resultant desire to 
cough. Understanding mechanisms that regulate urge-to-cough may therefore reveal opportunities 
to help relieve chronic cough in respiratory disease. 
 
Like cough, the urge-to-cough is subject to regulatory processes that play an important role in 
shaping its magnitude or characteristics.  For example, coughing and the urge-to-cough are 
markedly reduced by placebo antitussive treatments, suggesting the presence of inhibitory neural 
pathways that can modify processing of airway sensory inputs. In both clinical and experimental 
settings the magnitude of this reduction appears to be greater and more consistent than in placebo 
analgesia (Hróbjartsson & Gøtzsche, 2006; Vase et al., 2009), although the reasons for this are as 
yet unclear. Eccles (Eccles, 2002) concluded that the placebo antitussive effect is associated with 
improvements in cough-related symptoms averaging 85% of the benefits seen for active treatments 
in clinical trials. Perhaps most tellingly, we have shown that a placebo antitussive reduces the urge-
to-cough by 45% in healthy people inhaling a tussive agent under controlled experimental 
conditions (Leech, Mazzone, & Farrell, 2012).  It seems plausible that this reduction in urge-to-
cough contributes significantly to the effectiveness of placebos and/or therapeutics in reducing 
coughing in disease.  Therefore, understanding the mechanisms underlying these large placebo 
antitussive effects could have important implications for future development of active antitussive 
treatments. 
 
Despite repeated observations of an unusually large placebo antitussive response there has 
surprisingly been no published research into the underlying neurological basis of this effect.   We 
have previously described the neural networks involved in generating the urge-to-cough in humans 
using functional brain imaging (Mazzone et al., 2007), showing regional brain responses that are 
related to the intensity of tussive stimuli and magnitude of the perceived urge-to-cough (Farrell et 
al., 2012).  A logical prediction is that these brain responses should show selective decreases 
following placebo antitussive administration corresponding with changes in the perceived urge-to-
cough. Therefore, in the present study we set out to define the effects of placebo antitussive 
administration on the cough neural network and describe possible brain regions that generate 
placebo modulation of the urge-to-cough in humans.  
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Methods 
Participants 
Healthy adult volunteers with no history of smoking, chronic respiratory disease or recent 
respiratory infections were recruited. One subject was excluded due to gross neurological 
abnormalities identified during MRI, which would have precluded accurate registration and 
interpretation of imaging data. Data analysis was performed on the remaining 17 subjects (10 male, 
mean age 23.4 ± SD 6.6 years). Written informed consent was obtained via a modified “authorised 
deception” consent form (Miller, Wendler, & Swartzman, 2005). A full debriefing was provided to 
participants at the conclusion of each session and they were given the option to withdraw their data 
if they wished. No participant chose to use this option. All aspects of this study were approved by 
the Melbourne Health Human Research Ethics Committee (2011.100). 
 
Capsaicin sensitivity testing 
Individual cough thresholds were determined using single maximum capacity inhalations of 
doubling doses of nebulised capsaicin (Leech et al., 2012; Mazzone et al., 2011). After each 
inhalation participants rated their urge-to-cough on a modified Borg scale ranging from zero (no 
discernible urge) to ten (maximal urge). The ‘high dose’ of capsaicin for each individual was 
defined as the highest concentration that evoked a strong urge-to-cough but was not associated with 
reflex coughing when repeatedly inhaled during 16 seconds of continuous stimulation. The ‘low 
dose’ was one quarter of this concentration and used for conditioning as described below. 
 
Expectation, conditioning and testing 
As previously described (Leech et al., 2012), participants were informed they would on occasion 
receive lidocaine hydrochloride, a commonly used local anaesthetic that would substantially but 
briefly reduce their urge-to-cough during capsaicin challenges. The expectation of receiving an 
active treatment was enhanced using an information leaflet outlining possible side effects and 
contraindications of lidocaine. Participants were informed that they would receive capsaicin to 
induce the urge-to-cough and that there would be two types of trials: “lidocaine” and “no 
treatment”, differentiated by instructions projected on a screen in either green or red text, 
respectively. The “lidocaine” was in fact normal air (i.e., placebo antitussive), passively inhaled via 
a nasal cannula.  
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Participants were informed that the aim of the study was to test a prospective experimental protocol 
for use in chronic cough patients. Prior to the MRI session, participants completed 2 conditioning 
runs, each run comprising 3 control (‘high dose’ capsaicin and no expectation of treatment) and 3 
conditioning trials (‘low dose’ capsaicin preceded by placebo antitussive). Participants believed that 
they were receiving the ‘high dose’ on all trials and were informed that this session was aimed at 
familiarising them with the protocol. 
 
To control for breathing related artefacts, participants were instructed to use the same pattern of 
inhalation during no treatment trials. During conditioning placebo trials, participants unknowingly 
received the ‘low dose’ of capsaicin. During functional MRI the ‘high dose’ of capsaicin was given 
for all trials. Following the session participants were asked if they suspected they were not actually 
receiving lidocaine. All participants believed they received an active treatment. 
 
Image Acquisition 
Images were acquired with a Siemens Trio 3 Tesla scanner at the Murdoch Children’s Research 
Institute (Melbourne, Australia). Anatomical T1-weighted sagittal images were acquired for 
registration purposes (TR=1900 ms; TE=2.59 ms; 192 slices; 0.9mm thickness, 0.8 by 0.8mm in-
plane resolution). Functional images were obtained using an echo-planer imaging sequence (TR= 
2000 ms, TE=32 ms, slice thickness =4.50, 3.28 by 3.28 mm in-plane resolution, flip angle=90 
degrees, 216 volumes). 
 
Experimental Protocol 
During MRI sessions, participants completed 4 runs of 7min 12sec duration. Runs contained 2 
presentations each of control (‘high dose’ capsaicin and no expectation of treatment), placebo 
(‘high dose’ capsaicin preceded by placebo antitussive) and conditioning (‘low dose’ capsaicin 
preceded by placebo antitussive) trials, presented in a randomised order. Additional conditioning 
runs were included during the MRI session in order to sustain the placebo effect over the course of 
the scanning. 
 
During MRI scanning, participants were given on-screen instructions to rate their urge-to-cough 
following each trial by holding up the fingers of the right hand. Respiratory data (time-locked to 
both image acquisition and stimulus presentation) was collected using a respiratory belt (PowerLab 
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16/35 and LabChart (ADInstruments; http://www.adinstruments.com/) and analysed using 
LabChart and custom python scripts.  
 
Participants completed four runs, each consisting of randomised placebo, control and conditioning 
trials (Figure 9).  
 
 
Participants inhaled either a low or 
high dose of nebulised capsaicin for 
16s during six stimulus trials 
throughout a single run of functional 
brain image acquisition lasting 7 
minutes and 12 seconds.  All 
participants completed four scanning 
runs. Air was inhaled through a nasal 
cannula prior to each stimulus trial. A 
visual cue to participants indicated if 
lidocaine or normal air would be delivered through the nasal cannula.  However, participants only 
ever received normal air through the nasal cannula.  Low doses of capsaicin preceded by placebo 
lidocaine were used to sustain the conditioned belief that the treatment was effective.  High doses of 
capsaicin preceded by normal air constituted control trials.  Placebo antitussive trials consisted of 
high doses of capsaicin preceded by placebo lidocaine.  At the conclusion of each trial, participants 
were asked to indicate their rating of maximum urge-to-cough for the preceding stimulus using the 
fingers of the right hand (scale 0 to 10).   
 
Statistical Methods 
Behavioural analyses were carried out with PASW statistics (Release Version 18.0.0, SPSS, Inc., 
2009, Chicago, IL, www.spss.com) using repeated measures ANOVA.  
MRI analysis was performed using FEAT, Version 5.98, part of the FMRIB Software Library 
(FSL) (www.fmrib.ox.ac.uk/fsl/), using standard preprocessing and general linear modelling as 
described previously (see (Mazzone et al., 2011) for details). Briefly, preprocessing of EPI images 
consisted of realignment to correct for motion using a rigid body transformation, spatial smoothing 
with a 5mm full-width half-maximum Gaussian kernel, masking to remove non-brain tissue and 
high-pass temporal filtering with a cutoff of 0.01Hz. General linear modelling was carried out using 
Figure 9 - Experimental Design 
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FILM with pre-whitening to account for local autocorrelation (Woolrich, Ripley, Brady, & Smith, 
2001).  
 
Respiratory data was low-pass filtered with a cutoff of 0.5Hz and custom python scripts were used 
to establish individual timing regressors for each capsaicin or nasal inhalation period based on 
respiratory phase. This allowed us to deliver stimuli at regular intervals and later reconstruct the 
exact time point at which exposure to the stimulus began. This is a departure from our previous 
methods and avoided the need to cue subjects to begin inspiration at particular times; removing 
unnecessary breath holds that are known to introduce design-correlated respiratory artefacts (Abbott 
et al., 2005). Participants were instructed to breath normally throughout the session and were not 
given any cues that inhalation periods were about to begin. 
 
Timings for each trial were then retrospectively adjusted so as to begin immediately if the 
participant was already inhaling, or else at initiation of the next inhalation. Similarly, the end of the 
trial period was set to the conclusion of expiration. Respiration rates were examined for any 
potential differences between trial types and no significant differences were observed  
(F(2,32)=1.34, p=0.275; mean breaths per minute ± S.D.; control = 13.9 ± 3.2, conditioning = 13.9 
± 3.3, placebo antitussive= 13.6 ± 3.1). 
 
fMRI Analysis 
fMRI analysis was performed using approaches previously described (Farrell et al., 2012; Mazzone 
et al., 2011). Regressors were constructed for each of the capsaicin inhalation and nasal inhalation 
conditions (placebo, control and conditioning) as well as the rating period. In a first level analysis 
these regressors and their temporal derivatives were convolved with a hemodynamic response 
function and used to generate a model for each run.  
 
Additional regressors of no interest were included in the general linear model to account for any 
residual respiratory related noise as advocated by Birn (Birn et al., 2009). These consisted of six 
motion correction parameters, timecourses from cerebrospinal fluid (CSF) in the lateral ventricle 
and voxels of high standard deviation in the sagittal sinus, and mean global signal from non-
activated areas of the brain (Andersson, 1997). Contrasts were performed for each of the main 
conditions, as well as the differences between control and placebo capsaicin inhalation blocks. A 
second level fixed effects analysis was used to amalgamate results from all 4 runs for each subject. 
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Regional brain activations were identified for control trials, placebo trials, and the contrasts of 
control greater than placebo and placebo greater than control trials.  The association between 
participants’ behaviour and regional signal changes was tested by analysing the shared variance 
between placebo effects (urge-to-cough ratings during control trials minus ratings during placebo 
trials) and the levels of activation identified by the contrast of placebo greater than control trials. 
For group analysis, individual T1 weighted images were transformed into a standard space based on 
the MNI152 (Montreal Neurological Institute) template. Mixed effects analysis was then performed 
using FLAME across subjects to generate a group result. All statistical maps were thresholded to 
include voxels with a Z-value >2.3 and a cluster probability of p<0.05, corrected for multiple 
comparisons using Gaussian random field theory cluster-based correction as implemented in Feat 
(Worsley, Evans, Marrett, & Neelin, 1992). 
 
The relationship between placebo effects and activation for the contrast of placebo greater than 
control trials was examined with a region of interest (ROI) approach. An ROI was defined as those 
voxels in the dorsolateral prefrontal cortex that showed activation related to the difference between 
urge-to-cough ratings of placebo and control trials. Featquery was used to calculate percentage 
signal changes for the placebo greater than control contrast. Placebo effects on urge-to-cough 
ratings were ranked across the four scanning runs for each participant so that data could be 
amalgamated and used as independent variables in regression analyses to predict percentage signal 
changes from the regions of interest. 
 
Results 
Psychophysical Results 
Repeated measures ANOVA of urge-to-cough ratings during control and placebo trials showed a 
significant main effect of condition (F(1,16)=71.11, p<0.001). On average there was a 42% 
decrease in urge-to-cough ratings in placebo compared to control trials and a placebo antitussive 
effect was seen in all individuals (Figure 10). 
 
Figure 10 – Urge-to-Cough Ratings During Control and Placebo 
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Participants’ ratings of the urge-to-cough were 
averaged across the functional brain imaging runs for 
both control trials and placebo antitussive trials.  The 
figure shows the pair of ratings from individual 
participants represented as unbroken lines.  A 
downward slope to the right indicates a placebo-related 
decrease in the urge-to-cough.  All participants showed 
placebo-related decreases, and the average effect 
across the group is represented by the filled triangles 
connected by an unbroken line.  The variance bars on 
the triangles are standard errors of the mean. 
 
The geometric means of low and high capsaicin doses 
were 0.39μM and 1.66μM, respectively. The high 
stimuli were a dose increment less than the geometric mean of participants’ C2 doses (3.91 μM), 
which relates to increased levels of urge-to-cough and likelihood of coughing when participants 
inhaled capsaicin repeatedly compared to a single breath (see Table 2 for individual scanning doses 
and C2 thresholds). Titration of individual doses during preliminary trials successfully avoided any 
coughing events during scanning in all but one participant. Coughing during scanning in the one 
participant was managed by reducing the dose for placebo and control runs before further scans 
were acquired. 
 
Table 2 - Individual Capsaicin Doses 
Subject No Low Dose (µM) High Dose (µM) C2 Dose (µM) 
1 0.25 1.95 7.81 
2 0 0.98 0.98 
3 0.25 0.98 3.91 
4 0 0.98 1.95 
5 0.25 1.95 3.91 
6 0.735 3.91 3.91 
7 0.49 1.95 1.95 
8 0.25 0.98 0.49 
9 0.06 1.465 1.95 
 47 
10 0.49 1.95 3.91 
11 1.95 5.86 3.91 
12 0.25 0.98 15.63 
13 0.98 1.465 3.91 
14 0.25 0.98 1.95 
15 0.49 1.465 31.25 
16 1.465 5.86 *>62.5 
17 0.25 0.98 1.95 
Geometric Mean **0.39 1.66 3.91 
 
*   C2 of participant exceeded doses used in experimental protocol 
** Geometric mean calculated using non-zero values 
Definition of abbreviations:  
C2 – Dose of capsaicin that elicited 2 or more coughs on single maximal inhalation challenge. 
Regional Brain Activation During Control Trials 
Capsaicin inhalation during control trials was associated with widespread activation in a distributed 
urge-to-cough neural network, comparable to findings that we have previously reported (Farrell et 
al., 2012; Mazzone et al., 2007).  Thus, activations in the cerebral cortex included loci in the 
precentral and postcentral gyri (primary motor and sensory cortices, respectively), the insula, mid 
cingulate cortex, and orbitofrontal cortices, and the supplementary motor area (Table 3).  In 
subcortical regions, discrete activations were noted in the thalamus, midbrain, pons, medulla and 
cerebellum (Table 4).  
 
Table 3 - Regional Brain Activations for Contrast Control > Baseline 
 
   MNI Coordinates   
Region BA Side x y z Cluster Z Score 
Mid Cingulate Cortex 32 Right 4 18 42  5.01 
 24 Left -6 18 32 301 5.12 
 24 Right 4 16 32  4.46 
Medial Frontal Gyrus 6 Left -4 30 32  4.21 
Supplementary Motor Area 6  0 -4 60  3.31 
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Superior Frontal Gyrus 6 Left -16 -4 68  3.98 
 6 Right 26 2 66  3.94 
 9 Left -30 46 28  4.50 
 9 Right 30 54 30 34 4.68 
Middle Frontal Gyrus 6 Right 42 8 60  3.88 
 46 Left -36 40 26  4.53 
 46 Right 46 38 26 314 4.76 
 46 Right 38 32 22  4.60 
 10 Left -32 38 20 148 4.84 
 10 Right 36 44 0  5.86 
Orbitofrontal Cortex 11 Left -44 44 -14 16 3.67 
 11 Right 46 48 -16  4.37 
Inferior Parietal Lobule 40 Right 52 -40 46  4.26 
Cuneus 18  0 -88 28  4.15 
Precentral Gyrus 6 Left -54 -10 36  4.31 
 6 Left -42 -16 32  3.97 
 6 Right 40 -14 32  3.70 
 6 Left -44 -12 22  3.64 
 6 Right 40 -14 26 43 4.53 
 6 Right 58 4 18 155 5.04 
Postcentral Gyrus 2 Left -66 -18 28  3.44 
 1 Right 60 -16 22  3.98 
Central Operculum  Left -56 0 8 80 4.73 
  Right 60 2 10  4.56 
Superior Temporal Gyrus 22 Left -56 8 -2  4.26 
Insula 13 Left -36 16 -2  5.16 
 13 Right 36 20 0  6.09 
 13 Left -40 4 -10  5.24 
 13 Right 38 4 -6  5.37 
 
Definition of abbreviations:  
BA - Brodmann Area 
MNI Coordinates - The coordinates correspond to the Montreal Neuroscience Institute standard 
brain template where x values are distance in mm to the left (negative x values) or right (positive x 
values) from the anterior commissure, y represents mm distance anterior (positive) or posterior 
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(negative) from the anterior commissure and z is mm distance superior (positive) or inferior 
(negative) from the anterior commissure. The magnitudes of the peaks of clusters are represented 
by z statistics. The coordinates of the voxel with the highest level of activation within a cluster are 
listed. 
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Table 4 - Regional Subcortical Cerebellar and Brainstem Activations for Contrast Control > 
Baseline 
  MNI Coordinates   
Region Side x y z Cluster Z Score 
Globus Pallidus Left -14 0 -4  3.51 
 Right 14 2 -6  3.24 
Thalamus Left -16 -10 10  3.13 
 Right 14 -12 4  3.50 
Cerebellum       
Lobule VI Left -12 -66 -24 1908 5.22 
 Right 10 -64 -20  5.74 
 Left -32 -60 -40  5.81 
Dentate Left -20 -68 -26  6.33 
 Right 22 -60 -28  5.88 
Midbrain Left -10 -22 -6  3.23 
 Right 14 -18 -10  3.22 
Dorsal Pons Left -4 -36 -26  3.26 
 Right 8 -36 -26 34 3.71 
Rostral Medulla Left -6 -38 -50  4.75 
 Right 4 -38 -48  4.82 
Caudal Medulla  2 -42 -60 20 4.64 
 
Definition of abbreviations: See Table 3 for explanations 
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Regional Brain Activation During Placebo Trials 
In general, regions activated during placebo antitussive trials were similar to the network seen for 
control stimulus periods (Table 5).   
 
Table 5 - Regional Brain Activations for Contrast Placebo > Baseline 
   MNI Coordinates   
Region BA Side x y z Cluster Z Score 
Mid Cingulate Cortex 32 Left -6 18 38 182 5.56 
 32 Right 6 20 42  4.48 
Superior Frontal Gyrus 9 Left -30 48 28  3.80 
Middle Frontal Gyrus 6 Right 40 10 60 20 4.40 
 9 Right 34 52 34  4.50 
 46 Right 48 38 26 98 5.42 
 10 Left -36 58 14  4.27 
 46 Left -44 50 10  4.40 
 46 Right 46 54 8  4.86 
 10 Left -42 48 -8  4.55 
 10 Right 46 50 -10  5.31 
Orbitofrontal Cortex 10 Left -42 54 -16 17 4.68 
 10 Right 46 50 -16  5.43 
Inferior Parietal Lobule 40 Left -50 -48 54  4.56 
 40 Right 58 -50 48  4.19 
 40 Left -48 -42 34 19 4.35 
 40 Right 62 -46 38 23 4.04 
Cuneus 18  0 -90 28  4.00 
Precentral Gyrus 4 Left -40 -18 30  3.84 
 4 Right 40 -10 28  3.28 
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 6 Right 56 2 20  5.06 
Central Operculum  Left -56 0 8  4.56 
  Right 60 2 12  4.56 
Inferior Frontal Gyrus 47 Left -28 22 -10  5.26 
  Right 30 24 -8 380 4.75 
Insula 13 Left -32 4 4  4.36 
 13 Right 36 0 -8 21 4.29 
 13 Left -34 18 -4 248 5.40 
 13 Right 36 20 0  5.22 
Cerebellum        
Vermis VI  Left -2 -72 -14  5.38 
Lobule VI  Left -22 -68 -30 2427 5.98 
  Right 24 -62 -28  5.63 
  Left -30 -58 -38  5.70 
Dentate  Left -34 -62 -48  5.45 
Dorsal Pons  Left -6 -34 -26  3.10 
  Right 6 34 -22  3.12 
  Left -8 -38 -34  4.72 
  Right 10 -40 -34  4.72 
Rostral Medulla  Left -6 -38 -48 132 5.24 
  Right 6 -38 -48  4.60 
Caudal Medulla  Left -4 -42 56  4.89 
  Right 4 -42 -56  4.48 
 
Definition of abbreviations: See Table 3 for explanations 
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Mixed effects analysis showed significantly greater activation during control trials compared to 
placebo antitussive trials in regions including the primary and secondary somatosensory cortices, 
primary motor cortices, mid cingulate cortices and supplementary motor area (p<0.05, cluster 
corrected)(Figure 11 and Table 6). 
 
Table 6 - Regional Brain Activations for Contrast Control > Placebo 
 
   MNI Coordinates   
Region BA Side x y z Cluster Z Score 
Mid Cingulate Cortex 24 Left -2 2 42 215 3.88 
 24 Right 4 22 24  3.70 
Pregenual Cingulate Cortex 32 Left -2 38 8 10 3.68 
Superior Frontal Gyrus 6 Left -18 -4 62 14 3.84 
 6 Right 14 -8 64 52 3.62 
 9 Right 30 44 28 141 3.67 
Supplementary Motor Area 6  0 -4 58 48 3.95 
Precentral Gyrus 6 Left -52 -4 26  3.23 
 6 Right 54 -6 28  3.32 
Postcentral Gyrus 3 Left -50 -18 36  3.48 
 3 Right 52 -20 30  3.29 
 3 Left -56 -14 24 132 3.50 
 43 Left -60 -12 22  3.21 
 43 Right 58 -8 20  3.10 
Central Operculum  Left -60 -10 12  3.26 
  Right 54 2 8 138 3.77 
Parietal Operculum  Left -54 -22 22  3.25 
  Right 50 -24 28  3.21 
Cuneus 18 Right 4 -92 20  3.27 
Superior Temporal Gyrus 22 Left -54 8 -2 19 3.74 
Insula 13 Right 40 8 2  3.41 
 13 Right 42 -8 2  3.07 
Definition of abbreviations: See Table 3 for explanations 
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Figure 11 – Regional Decreases in Brain Activation Following Placebo 
 
 
 
 
 
Brain regions showing activation during control trials are rendered in red/yellow on an average of 
participants’ structural brain images that were warped to the standard dimensions of the Montreal 
Neuroscience Institute template brain.  A contrast was made between control and placebo 
antitussive trials to show regions where the level of activation was decreased after placebo 
lidocaine compared to control, the results of which have been rendered in blue on top of the 
structural image and control activations.  A. A sagittal slice through the left hemisphere shows 
placebo antitussive-related decreases in capsaicin activation in the supplementary motor area 
(SMA) and anterior cingulate cortex (ACC). These placebo antitussive-related decreases also 
occurred in the right hemisphere (not shown) B. The secondary somatosensory cortex (SII) in the 
parietal operculum showed bilateral decreases in capsaicin activation during placebo antitussive 
trials. C. The insula (INS) was activated in both hemispheres during control stimulus periods, but 
showed placebo antitussive-related decreased activation exclusively in the right hemisphere. D. 
Control activations in the primary motor (MI) and somatosensory (SI) cortices were reduced 
bilaterally during placebo antitussive stimulus periods.  A similar decrease was seen in the right 
superior frontal gyrus, but the same region in the left hemisphere did not show placebo antitussive-
related decreases. 
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Conversely, there was greater activation in placebo antitussive trials versus control trials in several 
brain regions including, the dorsolateral prefrontal cortices in the middle frontal gyri, the precentral 
gyri, the inferior frontal gyri, the left inferior parietal lobule and the cerebellum (p<0.05, cluster 
corrected)(Figure 12 and Table 7).  The levels of increased activation during placebo antitussive 
compared to control trials in the right middle frontal gyrus were positively correlated with placebo-
related changes in urge-to-cough ratings (p<0.05, cluster corrected). 
 
Table 7 - Regional Brain Activations for Contrast Placebo > Control 
 
•  •   MNI Coordinates  
Region BA Side x y z Z Score 
Middle Frontal Gyrus 6 Left -36 10 54 3.32 
 6 Right 40 6 50 3.44 
 9 Left -40 20 36 3.35 
 9 Right 46 26 34 *3.52 
 9 Right 46 32 28 *3.19 
Inferior Frontal Gyrus 45 Left -40 22 22 3.75 
 9 Left -46 12 26 3.46 
 9 Right 40 8 26 3.15 
Precentral Gyrus 6 Left -40 4 34 3.20 
 6 Right 36 4 34 3.22 
Inferior Parietal Lobule 40 Left -50 -54 50 3.53 
 40 Left -34 -56 46 3.11 
Middle Temporal Gyrus 39 Left -32 -58 32 3.24 
Cerebellum  Right 26 -88 -34 3.84 
 
Definition of abbreviations: See Table 3 for explanations 
* Clusters that showed levels of activation that were correlated with behavioural measures of 
placebo antitussive effects 
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Figure 12 - Regional Increases in Brain Activation Following Placebo and Correlations 
with Behavioural Measures 
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Voxels shaded in green indicate regions where capsaicin activation was increased during placebo 
antitussive trials compared to control trials.  Blue voxels denote regions where the size of the 
placebo antitussive increase in brain response was correlated with the size of the behavioural 
measures of placebo effects.  Regions that showed placebo antitussive-related increases in 
capsaicin activations as well as correlations with the behavioural measures are shown in red.  A. 
The posterior parietal cortex (PPC) in the left hemisphere and the precentral gyrus (PreC) 
bilaterally showed increased levels of placebo antitussive trial activation compared to control 
trials.  The middle frontal gyrus (MFG) in the right hemisphere showed placebo antitussive-related 
levels of activation that correlated with the size of behavioural placebo effects measured with urge-
to-cough ratings.  B. Placebo antitussive trial-related increases in activation greater than control 
trials were seen bilaterally in the middle frontal gyri (MFG) in this axial slice 52mm above the 
anterior commissure. These symmetrical regions of activation did not show levels of activation that 
correlated with behavioural measures of the placebo antitussive effect. C. An extensive region of 
the right middle frontal gyrus (MFG) in the dorsolateral prefrontal cortex showed levels of placebo 
antitussive greater than control trial activation that was correlated with behavioural measures of 
placebo effects.  D. The mean ratings of urge-to-cough by a participant for placebo antitussive 
trials during a scanning run were subtracted from the mean of the control trials in the same run to 
derive a behavioural measure of placebo effect (ΔUrge-to-Cough). Blood oxygen level-dependent 
(BOLD) signal changes for the contrast of placebo greater control trials (Δ%BOLD Signal 
Change) were extracted for voxels showing correlation with the behavioural placebo effect. The 
relationship between behaviour and regional brain activation is represented in the scattergram 
where the four runs were ranked according to behavioural placebo effects from smallest to largest 
and then plotted against the mean BOLD signal changes for the corresponding runs.  
Discussion 
The brain plays an important role in both the processing of incoming sensory information arising 
from the airways and lungs and in generating motor outputs that contribute to the behavioural 
regulation of respiration.  These central processes are not confined to the brainstem but rather 
involve all levels of the neuraxis (Davenport & Vovk, 2009; Mazzone et al., 2013)  With respect to 
cough, information from the airways can be encoded into a conscious awareness of airway 
irritations leading to the generation of an urge-to-cough (Davenport et al., 2002), which may then 
facilitate behavioural or evoked coughing in order to help clear the airways (Hegland, Bolser, & 
Davenport, 2012).  Components of this higher brain circuitry also comprise inhibitory mechanisms 
that can be consciously or subconsciously recruited to suppress cough neural processing in the brain 
(Mazzone et al., 2011).  This suppression may lead to either a reduction in the encoding of 
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incoming sensory information, which would predictably lower the urge-to-cough, or a reduction in 
the outgoing motor commands that lead to a top down inhibition of coughing.  Indeed the available 
evidence indicates that central inhibitory mechanisms are capable of an impressive level of cough 
suppression (Eccles, 2002; Hutchings et al., 1993), suggesting that opportunities may exist to 
harness or mimic these processes as novel therapeutic approaches to achieve cough suppression in 
disease.  
 
In the present study we confirmed our previous findings (Leech et al., 2012) that the perceptual 
component of airway sensory irritation (urge-to-cough) is significantly modifiable by placebo 
antitussive treatments.  Thus, the belief in a therapeutic is seemingly sufficient to reduce the 
encoding of urge-to-cough intensity in the brain.  In support of this, the results from our functional 
brain imaging studies revealed that the magnitude of brain activations in a number of central loci 
involved in generating the urge-to-cough were significantly reduced by placebo antitussive 
administration.  Furthermore, we showed that when participants believed that they were receiving 
an antitussive treatment, brain activity was increased in regions of the prefrontal and parietal 
cortices that may represent important components of the placebo suppression network (Benedetti, 
Mayberg, Wager, Stohler, & Zubieta, 2005; Krummenacher et al., 2010).  These data represent the 
first insights into the neurobiological mechanisms that contribute to placebo antitussive responses 
and reinforce the notion that multiple central inhibitory mechanisms exist for modifying cough in 
humans. 
 
Placebo antitussive suppression of the urge-to-cough 
The urge-to-cough is an important component of coughing that serves to inform individuals of the 
presence of irritants in the airways.  Studies in the laboratory have shown that common tussive 
challenges (e.g., capsaicin) can be used to evoke an urge-to-cough in a dose-dependent fashion 
(Davenport et al., 2002; Farrell et al., 2012).  Furthermore, the urge-to-cough typically precedes the 
motor act of coughing, perhaps arguing that it plays a pivotal role in governing whether patients 
cough or not in response to sensory input from the airways (Davenport, 2008).  
 
In the present study we noted a 42% reduction in the mean capsaicin-evoked urge-to-cough ratings 
following placebo antitussive administration.  This response is highly comparable to our previous 
work, which was performed using an entirely separate cohort of participants (Leech et al., 2012).  In 
both studies we employed a standard conditioning strategy to reinforce expectations that the 
placebo treatment was in fact an efficacious antitussive therapy.  Using this strategy we have yet to 
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identify any participants who do not report a decrease in urge-to-cough ratings following placebo 
antitussive trials.  These experimental data resemble data obtained from clinical trials that report a 
high rate of placebo responses to antitussive therapies (Eccles, 2002), adding support to our 
assertions that cough is particularly amenable to suggestive suppression.  Indeed, cough may be 
more susceptible than pain to the effects of placebos, since placebo analgesia studies typically 
report that only around 50% of subjects experience a modest reduction in pain scores (Wager et al., 
2004).  
 
It is unclear at present why cough neural networks display such a high sensitivity to placebo 
antitussive suppression.  It is worth noting that behavioural aspects of placebo suppression have not 
been studied in detail for cough.  In this regard, we do not know whether the magnitude of placebo 
antitussive suppression varies depending on the magnitude of the initial stimulus.  In other words, it 
is plausible that the placebo effect diminishes in participants when evoked cough approaches 
challenge thresholds that would elicit uncontrollable reflex coughing (and therefore very strong 
urge-to-cough sensations).  Furthermore, it is simply not known whether patients with a cough 
disorder are equally sensitive to placebo antitussive suppression.  Nevertheless, the size of the urge-
to-cough reduction reported in our studies of healthy participants is not dissimilar to the magnitude 
of placebo contribution to cough suppression reported in many clinical trials of antitussive 
therapies, including in patients with chronic cough (Kuhn, Hendley, Adams, Clark, & Gwaltney, 
1982; Lee et al., 2001; Parvez, Vaidya, Sakhardande, Subburaj, & Rajagopalan, 1996).  
It has been speculated that decreased anxiety or attention may play a role in placebo analgesia 
(Flaten, Aslaksen, Lyby, & Bjorkedal, 2011). Indeed our paradigm shares some similarities with 
“threat of pain” studies (Ploghaus et al., 2001).  Most notably, the preparatory cues used in our 
study could have primed emotional responses in anticipation of stimuli. However, it is difficult to 
make direct comparisons between the activation outcomes of the other studies and our own because 
threat of pain studies focus on adverse, anxiety-related responses, whereas our study investigated 
expectations of relief. Nevertheless, given that anxiety is known to influence cough (Van den Bergh 
et al., 2012), then reduction in anxiety may have played a role in producing the placebo antitussive 
effects observed in this study, and indeed could feasibly also contribute to the placebo effects seen 
in clinical trials (Watson et al., 2009). 
 
This study used a conditioning strategy common to experimental placebo manipulations (Wager et 
al., 2004), where, rather than using an active drug, conditioning was achieved by means of pairing a 
visual cue with a reduced level of stimulus. As an initial investigation into the neural mechanisms 
underlying placebo in urge-to-cough, our design incorporated both enhanced expectation and 
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conditioning in order to maximize the size of the observed effect. Further investigation into the 
behavioural and neural responses to either conditioning or expectation alone may be instructive in 
elucidating the relative contributions of each to the behavioural effect, and also whether activation 
changes in similar cortical regions are involved.  Although it is possible to design studies dissecting 
the relevant contributions of these mechanisms towards experimental placebo effects, it may be 
more difficult to conceptually separate them in clinical settings. For example, prior experience 
using ineffective antitussives may lead not only to negative expectations surrounding treatment, but 
may indeed be thought of as a form of conditioning, whereby patients are conditioned to associate 
treatment with a lack of effect (Colloca & Benedetti, 2006). 
 
Regional brain responses during capsaicin inhalation and the effect of placebo 
The urge-to-cough relies on subcortical and cortical processing of incoming sensory information 
from the airways (Farrell et al., 2012; Mazzone et al., 2007; Wheeler-Hegland, Pitts, & Davenport, 
2010). We have previously reported that subcomponents of this broader urge-to-cough network can 
be delineated that show activations encoding for the sensory discriminative, cognitive and motor 
aspects of airways irritation.  For example, based on differential responses to varying levels of 
tussive stimuli, we have shown that distinct parts of the network activated by capsaicin inhalation 
are responsible for grading stimulus intensity (e.g., anterior insula cortex), determining urge-to-
cough intensity (e.g., primary sensory cortex) and processing spatial or higher order processes such 
as those related to attention and motivation (e.g., the inferior parietal lobule and prefrontal 
cortex)(Mazzone et al., 2013).  We have also identified discrete regions within the right inferior 
frontal gyrus and anterior insula as forming part of an endogenous cough suppression network that 
can be voluntarily recruited to reduce motor outputs driven by the urge-to-cough (Mazzone et al., 
2011) and the mid cingulate cortex as a key hub area that may help integrate all of these functions 
of the urge-to-cough network (Farrell et al., 2012).   
 
The results of the present study suggest that the different components of the urge-to-cough network 
do not respond uniformly in response to placebo antitussive administration.  For example, 
capsaicin-related activations following placebo antitussive administration were significantly 
reduced in several sensory and motor regions, including the insula, anterior cingulate cortex, 
primary somatosensory and motor cortices and the supplementary motor area.  By contrast, placebo 
increased the activity in the middle frontal gyri (specifically in the region containing the 
dorsolateral prefrontal cortex, Brodmann area 9) and in the inferior parietal lobule and precentral 
gyrus.  These findings might reflect regional responses that are responsible for the behavioural 
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outcomes following placebo antitussive administration. Thus, the reduction in urge-to-cough ratings 
reported by participants following placebo presumably reflect the relatively lower amount of 
activation seen in the urge-to-cough sensorimotor brain regions.  Furthermore, these reductions may 
be related to the heightened activity noted elsewhere in the urge-to-cough network.  Indeed, placebo 
analgesia studies similarly report elevated brain activity in the dorsolateral prefrontal cortex and 
inferior parietal lobule, suggesting that these regions may play an important role in regulating 
sensorimotor responses in the brain (Amanzio, Benedetti, Porro, Palermo, & Cauda, 2013). 
 
Consistent with this, the magnitude of the activation in the right dorsolateral prefrontal cortex in the 
present study was significantly correlated with the magnitude of the reported placebo antitussive 
effect. Alternatively, regions including the right ventral inferior frontal gyrus, neighbouring anterior 
insula and the more anterior extent of mid cingulate activation, regions which have been implicated 
in cough and breathing suppression (Mazzone et al., 2011; McKay, Adams, Frackowiak, & 
Corfield, 2008), did not show differences between placebo and control trials.  
 
These results point to similarities in the mechanism of action of placebos between pain and urge-to-
cough. The decreases in activation in capsaicin inhalation networks can be compared to results from 
placebo analgesia studies, where the network of pain-related brain regions shows decreased 
activation in response to painful stimuli following placebo (Lu et al., 2010; Lui et al., 2010; Wager 
et al., 2004).  Studies of placebo effects in pain have also shown increased activation in the 
dorsolateral prefrontal cortex (Wager et al., 2004; Watson et al., 2009) in the placebo condition. 
Furthermore, placebo analgesia is abolished when transcranial magnetic stimulation is used to block 
neural transmission in this region (Krummenacher et al., 2010).  
 
Interestingly, there were no statistically significant decreases in brain activity noted in thalamic or 
subcortical structures when responses following placebo antitussive administration were compared 
to no-treatment responses. This might suggest that placebo antitussive circuits function by 
selectively reducing cortical processing of incoming sensory information.  However, the data might 
also reflect the scanning parameters employed, which were optimised for whole brain imaging 
rather than discrete imaging of subcortical and lower brain structures. Consistent with this, several 
thalamic and brainstem regions displayed responses approaching statistical significance following 
placebo antitussive administration, which may be better resolved using an acquisition protocol 
optimised for this purpose. 
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Concluding Remarks 
Placebo antitussives have a strong influence on coughing and the urge-to-cough.  The outcomes of 
this study have shown that the substantial reductions in urge-to-cough after placebo are matched by 
a parallel decrease in brain responses to capsaicin inhalation in regions coding sensation and 
processing motor outputs.  This confluence of behaviour and brain activity points toward an active 
inhibitory process that is likely mediated by prefrontal cortex, parietal cortex and the cerebellum.  
Of those regions implicated in the placebo antitussive effect, activity in the right dorsolateral 
prefrontal cortex appears to have a special significance and constitutes a promising target for future 
studies. The study of higher brain mechanisms in cough has the potential to expand our 
understanding of a number of clinical conditions such as chronic idiopathic cough or chronic cough 
associated with COPD. In addition, it is highly likely that these mechanisms are involved in 
excessive cough syndromes with a psychological or behavioural component including psychogenic 
or habit cough, as well as disorders of abnormal cough down regulation or suppression such as 
Lady Windermere syndrome (Davenport, 2008; Van den Bergh et al., 2012; Weinberger, 2012). As 
these disorders are particularly difficult to treat, understanding the neurological basis of placebo 
suppression of urge-to-cough may be a promising avenue for developing or evaluating tools such as 
biofeedback, cognitive behavioural therapy or perhaps other behavioural therapy (e.g. speech 
therapy) that aim to establish a normal cough reflex. Further research may also prove useful for 
developing novel CNS drug targets.
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Chapter 5 - Brainstem Activity Associated with Placebo Suppression of the 
Urge-to-Cough 
 
Introduction 
 
Administration of a placebo decreases the behavioural response to tussive stimuli, as well as 
causing a reduction in activation in urge-to-cough related brain regions such as somatosensory 
cortex. The placebo effect in urge-to-cough appears to be mediated by inhibitory processes 
involving parts of the prefrontal and parietal cortices. The right dorsolateral prefrontal cortex in 
particular is correlated with the strength of the observed effect. It is, however, unclear whether this 
inhibition is caused by a reduction in the transmission of urge-to-cough sensory information from 
the periphery to the cortex by descending inhibition of brainstem respiratory centres, or whether it 
is due to purely cortical inhibitory mechanisms. If inhibition of brainstem regions is implicated in 
producing placebo reduction of the urge-to-cough, then changes in processing in these pathways 
could feasibly be implicated in the excessive urge-to-cough seen in patients with chronic cough 
disorders.  
 
The sensation of urge-to-cough is initiated by irritation in the airways activating peripheral sensory 
nerve receptors that are sensitive to either mechanical or chemical stimulation. Vagal afferent 
nerves convey these signals to the brainstem, where information is integrated before being relayed 
to the cortex. A distributed network of cortical regions further processes this information, 
incorporating psychological and social variables such as emotional state and social context. This 
process ultimately results in either suppression of the urge-to-cough, recognition of the urge-to-
cough without motor output, or activation of the cough motor pattern generator in the brainstem, 
leading to reflex cough. 
 
These vagal afferent nerves from the airways first synapse with second order neurons in the nTS. 
The region of the nTS in receipt of airway afferents is the caudal medial part of the nucleus rostral 
to obex (Canning & Mori, 2010).  As the first CNS point of synapse where sensory input from the 
airways could be modulated, the nTS has been proposed as the most likely site for sensory 
integration and gating of the cough motor response (Bonham, Sekizawa, Chen, & Joad, 2006). 
Given the nTS receives peripheral sensory information, as well as thalamic and cortical input, it 
presents a likely candidate region for cortically mediated placebo suppression of the urge-to-cough. 
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Information from the airways is first integrated via local neuronal assemblies in the nTS, and the 
resulting signals are then relayed to neurons in the reticular formation, the parabrachial complex, 
particularly the Kolliker-Fuse nucleus (Torvik, 1956), and regions of the ventrolateral medulla that 
are related to respiratory control (Shannon, Baekey, Morris, & Lindsey, 1998). Additionally the 
nTS has projections to the hypothalamus, thalamus and amygdala (Canning, 2007; Mazzone & 
Canning, 2002; Ohi et al., 2005).  
 
The nTS also receives direct projections from insular cortex, hypothalamus, amygdala, medial 
prefrontal cortex and lateral prefrontal cortex (Otake & Nakamura, 2003; Van Der Kooy, McGinty, 
Koda, Gerfen, & Bloom, 1982; Vanderkooy, Koda, McGinty, Gerfen, & Bloom, 1984), making it 
an ideal candidate region for top-down placebo related inhibition. Notably, these connections 
involve the commissural, or most caudal part of the nTS that receives inputs from airways afferents. 
Inhibition at this first synaptic level of sensory integration in the brainstem would cause decreased 
activation in all downstream regions of cough sensory processing, as was seen in our previous 
whole brain MRI study. 
 
A model of the central reflex pathway regulating cough has been proposed (Bolser & Davenport, 
2002; Shannon et al., 1998) that suggests sensory afferents converge on a putative gating 
mechanism via nTS relay neurons.  Gated signals then pass to the central cough pattern generator. 
This proposed gating mechanism presents one possible point of placebo inhibition. Short-term 
neuronal plasticity in the nTS may contribute to heightened responses to tussive stimuli, or to the 
suppression of cough (Bonham et al., 2006; Bonham, Sekizawa, & Joad, 2004).  Long-term 
plasticity in these neurons could also feasibly be responsible for the responses to normally 
innocuous stimuli seen in chronic cough patients (Bonham et al., 2006) 
 
Newer studies using recombinant viral tracing have also shown that afferent neurons from the 
trachea can additionally be traced to the trigeminal and paratrigeminal nuclei in the medulla 
(McGovern et al., 2012). As there is evidence that these neurons relay sensory information to the 
thalamus via trigeminothalamic tracts (Cechetto & Saper, 1987), this represents an alternative 
pathway where inhibition could occur. Using anterograde viral tracing from tracheal afferent 
neurons, cells were labelled initially in the nTS and trigeminal/paratrigeminal nuclei. Secondary 
labelling occurred in the pons (lateral and medial parabrachial nuclei), thalamus, hypothalamus and 
amygdala, before being labelled in higher cortical regions including somatosensory, orbital, insula 
and cingulate cortices (McGovern et al., 2012).  
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Most of what is known about the brainstem circuitry that produces an urge-to-cough comes from 
animal models and has not yet been studied in humans. Thus, in addition to the brainstem nuclei 
already mentioned, other nuclei involved in respiratory and cough control could possibly play a role 
in the sensory perception of urge-to-cough. Reflex cough is produced by a brainstem respiratory 
network normally involved in regulating breathing (Shannon et al., 2004). This widespread network 
includes neurons in the ventrolateral medulla (including the Bötzinger and pre-Bötzinger 
complexes) that are normally responsible for respiratory pattern generation, the raphe nuclei in the 
caudal medulla and lateral tegmental field, as well as pontine respiratory centres and the cerebellum 
(Bolser & Davenport, 2002). The pontine respiratory group in the rostral dorsal lateral pons 
(including the Kölliker-Fuse nucleus) is also involved in maintaining a normal breathing pattern, 
and appears to be essential for producing reflex cough (Poliaček et al., 2004). 
 
In this study our aim was to determine whether placebo inhibition of urge-to-cough occurs due to 
cortico-cortical inhibition, or whether descending inhibition of subcortical regions is also involved. 
If the placebo effect causes inhibition at a subcortical level, we would expect to see less activation 
in brainstem nuclei involved in relaying sensory information to the cortex. If on the other hand the 
placebo effect is mediated by purely cortical mechanisms, we would expect to see similar patterns 
of activation in brainstem regions during both placebo and no treatment (i.e. less activation in the 
cortex, given the same input from subcortical regions). This information could assist in assessing 
and targeting therapeutic interventions in chronic cough patients aimed at reducing the sensation of 
urge-to-cough without impairing reflex cough.  
Methods 
Participants 
16 healthy, non-smoking subjects with no history of respiratory disorders participated in the 
experiment (6 male, mean age ± s.d. =24.25 years ± 4.78 years). This study was approved by the 
Melbourne Health Human Research Ethics Committee (2013.078). In line with best practise in the 
use of deception in research, subjects were fully debriefed at the end of the session, both verbally 
and in writing. Participants were also given the opportunity to withdraw their data from the study if 
they so wished. None of the participants chose to use this option. 
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Capsaicin threshold testing 
Individual perceptual and cough thresholds were tested with single maximal capacity inhalations of 
nebulised capsaicin in doubling doses ranging from 0.12 to 62.5 µM. Following each inhalation 
participants were instructed to rate their urge-to-cough on a modified Borg scale ranging from zero 
(no urge) to ten (maximum urge). The urge-to-cough threshold (Cu) was defined as the first 
instance where participants reported an urge-to-cough, while the cough threshold (C2) was the first 
dose that provoked two or more coughs. In the subsequent fMRI session the high dose used was the 
maximum concentration of capsaicin that could be tolerated without causing reflex cough. The low 
dose was one quarter of this concentration. Doses were adjusted as necessary if participants showed 
sensitisation or habituation across the course of the session. The individual low and high doses 
reported are the mean doses received by each participant during the session. 
 
Image Acquisition 
Images were acquired with a 3T Siemens Trio at the Royal Children’s Hospital in Parkville, 
Melbourne, Australia. Structural images consisted of sagittal T1-weighted whole brain images 
(TR=1900 ms, TE=2.59ms, 192 slices, 0.9mm thickness, 0.8x0.8mm in-plane resolution).   
Functional runs were collected using a partial FOV (See Chapter 2 for more details) with a 
gradient-echo echo-planar parallel imaging sequence (GRAPPA, PAT factor=3, reference lines=36, 
TR=1790ms, TE=30ms, 27 slices, 2.5mm thickness, 1.88mm in-plane resolution, flip angle=70 
degrees). Three whole brain EPI images with the same resolution as the functional runs were also 
collected. The mean of these images was used for an initial registration of the partial FOV images 
to the whole brain. 
 
Conditioning 
Conditioning was carried out as per the previous experiment. Briefly, each participant underwent 
two conditioning runs, with each run consisting of three no-treatment trials and three lidocaine 
trials. Participants were informed that they would receive the same capsaicin dose in every trial, 
preceded by either lidocaine or no-treatment. In fact, participants received either no-treatment 
followed by a moderate dose of capsaicin, or placebo followed by a low dose of capsaicin. 
 
Identification of Brainstem Regions Involved in the Placebo Effect on Urge-to-Cough 
Participants completed three fMRI runs, each consisting of three presentations each of control (no-
treatment followed by high dose capsaicin), conditioning (treatment followed by low dose 
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capsaicin) and placebo (treatment followed by high dose capsaicin), presented in a randomised 
order.   
 
Participants were informed via a projector running PsychoPy software (Peirce, 2008) at the 
beginning of the lidocaine or control nasal inhalation periods, during capsaicin inhalation, and when 
they were required to rate their urge-to-cough. Control trials were differentiated from placebo and 
conditioning trials by the use of red and green text, respectively. At all other times participants were 
instructed to remain focused on a fixation cross that matched the colour of the current trial type. 
Participants were thus constantly aware of which trial they were currently completing. 
 
Statistical Analysis 
Psychophysical analysis was carried out using ezANOVA software 
(http://www.mccauslandcenter.sc.edu/mricro/ezanova/). fMRI analysis was carried out using the 
FMRIB suite of software tools (www.fmrib.ox.ac.uk/fsl/). Preprocessing of functional EPI data 
consisted of motion correction with McFlirt, spatial smoothing with a 4mm full-width half-
maximum Gaussian kernel and high pass filtering with a 100s cutoff.  
 
Respiratory data was low-pass filtered with a cutoff of 0.5Hz and LabChart (ADInstruments; 
http://www.adinstruments.com/) was used to determine the timing of maximal inhalation and 
exhalation. Custom python scripts were then used to establish individual timing regressors for each 
capsaicin or nasal inhalation period based on respiratory phase (See Chapter 2 for more detail).  
 
Registration 
Functional EPI data was first linearly registered to the mean whole brain EPI using FLIRT with 
three degrees of freedom. An initial transformation linearly registered the whole brain EPI to each 
subject’s anatomical T1 scan using boundary-based registration (BBR)(Greve & Fischl, 2009), then 
FNIRT (Andersson, Jenkinson, & Smith, 2010) was used to non-linearly register the individual T1 
images to a standard 1mm brain template (MNI152) in order to preserve spatial resolution. 
 
General Linear Modelling 
General linear modeling was carried out using FILM with pre-whitening to account for local 
autocorrelation (Woolrich et al., 2001). Nuisance regressors included 6 motion realignment 
parameters and any volumes where excessive motion occurred as implemented in 
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FSLMotionOutliers. Additional regressors of no interest included to account for physiological noise 
consisted of motion corrected but otherwise unprocessed timecourses from a voxel of high standard 
deviation in the sagittal sinus, voxels located in the lateral ventricles and a voxel of high standard 
deviation in each carotid artery. 
 
Regressors were also created for each condition of interest: the period of capsaicin inhalation 
following control, placebo or conditioning; the period of “lidocaine” inhalation during control, 
placebo or conditioning; and the period were subjects were asked to rate their urge-to-cough. 
Regressors and their temporal derivatives were convolved with a canonical HRF. Contrasts were 
created for each of these regressors as well as the differences between control and placebo capsaicin 
inhalation periods. The resulting statistical maps covering the entire FOV were thresholded at 
p<0.05 corrected for multiple comparisons using FWE, in order to compare activation in cortical 
regions to those from the previous study (Chapter 4). 
 
As the brainstem regions involved in urge-to-cough have not been sufficiently well localised in 
humans to define a priori regions for statistical small volume correction, statistical maps for the 
relevant contrasts were first masked with an inclusive mask consisting of brainstem areas activated 
during all capsaicin inhalation periods obtained from the previous whole brain study (Leech, 
Farrell, & Mazzone, 2013)(Chapter 4). Masked statistical maps were then thresholded using 
permutation methods as implemented in Randomise (Winkler, Ridgway, Webster, Smith, & 
Nichols, 2014). Individual COPE images from the general linear model were fed into a separate 
Randomise analysis with 5000 permutations. Results were thresholded at p>0.05, corrected for 
multiple comparisons using FWE, with a cluster extent of greater than 10 voxels. An analysis of 
correlation with behavioural measures added an additional variable consisting of the average 
change in urge-to-cough ratings (percent change in ratings between placebo and control trials) for 
each participant (demeaned over all participants) as a measure of the strength of placebo effect. 
 
Results 
Psychophysical Results 
Repeated measures ANOVA of urge-to-cough ratings during control and placebo trials showed a 
significant main effect of condition (i.e. control versus placebo)(F(1,15)=22.10, p<0.005). There 
was an average decrease in urge-to-cough ratings of 27% in placebo compared to control trials. The 
geometric means of low and high capsaicin doses used during the scanning procedure were 0.40μM 
and 1.83μM, respectively. The high stimuli were, in all but one participant, equal to or lower than 
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the individual’s C2, reflecting both the increased likelihood of coughing when participants are 
exposed to continuously inhaled capsaicin compared to single maximum capacity inhalation, and 
the experimental procedures that aimed to minimise coughing during the MRI scan by reducing the 
capsaicin dose if participants began to cough. Conversely, the relationship of the low dose to Cu 
was much more variable, with four participants having a low dose equal to their Cu, four 
participants having a low dose higher than their Cu, and the remaining eight participants having a 
low dose below their Cu. This is likely to reflect the difficulty of perception at near threshold doses 
of stimuli, as similar to the high dose, experimental procedures were followed where the low dose 
was increased if participants began to consistently rate the stimuli as zero. See Table 8 for 
individual thresholds and doses used during scanning. 
 
Table 8 - Individual Capsaicin Doses 
Subject No Average Low 
Dose (µM) 
Average High 
Dose  (µM) 
Cu Dose (µM) C2 Dose (µM) 
1 0.33 1.31 0.49 3.91 
2 0.12 0.74 0.25 31.25 
3 0.49 1.95 0.49 1.95 
4 0.49 1.63 0.25 31.25 
5 0.25 1.95 0.25 1.95 
6 0.98 5.86 0.49 7.81 
7 0.71 2.85 0.49 7.81 
8 0.49 1.95 0.49 7.81 
9 0.25 1.47 0.25 7.81 
10 0.49 1.95 1.95 3.91 
11 0.09 0.82 0.49 1.95 
12 0.20 0.57 0.25 0.49 
13 0.12 0.49 0.25 1.95 
14 0.25 1.11 0.98 3.91 
15 4.34 18.25 1.95 *>62.5 
16 0.98 3.91 3.91 32.50 
Geometric 
Mean 
0.40 1.83 0.54 **6.04 
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*   C2 of participant exceeded doses used in experimental protocol 
** C2 of 62.5 µM was used in calculating geometric mean for Subject 15  
Confirmation of Placebo Related Changes in Activation in Expected Cortical Regions 
Whole brain regions showing activation were restricted to the FOV acquired during functional runs, 
optimised for the brainstem. While this FOV did not cover many of the regions investigated in the 
whole brain study (for instance the DLPFC), the activations for the contrast control>placebo 
showed similar differences in activation to those seen in the whole brain study e.g. somatosensory 
and premotor cortices (Table 9)(See Chapter 2 for FOV information). No significant differences in 
activation were seen for the contrast placebo>control. This was the expected result, as the FOV did 
not cover the regions implicated in placebo suppression of urge-to-cough (PPC and DLPFC, see 
Chapter 4). 
 
Table 9 - Regional Brain Activations for Contrast Control > Placebo 
   MNI Coordinates Cluster Size 
(Voxels) Region BA Side x y z 
Mid Cingulate Cortex 32 Left -5 -42 5 1132 
 32 Right 0 -37 38 806 
Superior Frontal Gyrus 9 Left -5 -3 71 765 
Middle Frontal Gyrus 6 Right -49 -54 -39 531 
 9 Right 2 -59 -36 529 
 46 Right -53 -9 36 517 
 10 Left -60 -31 18 454 
 46 Left -58 -22 24 450 
 
Definition of abbreviations:  
BA - Brodmann Area 
MNI Coordinates - The coordinates correspond to the Montreal Neuroscience Institute standard 
brain template where x values are distance in mm to the left (negative x values) or right (positive x 
values) from the anterior commissure, y represents mm distance anterior (positive) or posterior 
(negative) from the anterior commissure and z is mm distance superior (positive) or inferior 
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(negative) from the anterior commissure. The coordinates of voxels with the highest level of 
activation within a cluster are listed. 
 
Decreased Brainstem Activation During Capsaicin Inhalation Following Placebo 
Significant activations for the contrasts control > baseline and placebo > baseline were seen in a 
range of regions in the medulla and pons. The magnitude and extent of significant activation was 
greater in the control condition than in the placebo condition (Figure 13). 
 
Figure 13 - Capsaicin Related Brainstem Activation Following Placebo and Control 
 
 
 
Capsaicin related activation during control (red) and placebo (blue). Shown at visualisation 
threshold of p<0.005, uncorrected. Images are displayed in radiological convention (right side of 
the image shows the left side of the brain)  
A) Sagittal slice showing brainstem region of interest. B) Sagittal brainstem slice showing 
control>baseline activation in midbrain, medulla, cerebellum and pons; and placebo>baseline 
activation in caudal medulla. C) Coronal slice showing bilateral medullary and pontine activation 
in contrast control>baseline and placebo>baseline activation in caudal medulla. 
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Mixed effects analysis of the contrast control > placebo showed significantly less activation 
following placebo in a subset of these regions. These included a number of respiratory-related 
pontine and medullary structures (Table 10 and Figure 14). 
Figure 14 – Regional Decreases in Brainstem Activation Following Placebo 
 
A) Sagittal cross-sections showing brainstem regions with significantly decreased capsaicin 
induced activation following placebo. Shown at a visualisation threshold of p<0.005, uncorrected. 
Activation maps are overlaid on standard MNI brain template. Images displayed in radiological 
convention (right side of brain is displayed on the left of the image). Lines indicate level of 
respective axial cross-sections. B) Axial cross-sections showing pontine and medullary activation. 
 
Correlation of Regional Placebo-Induced Signal Reduction with Behavioural Measures 
The decrease in activation following placebo was also significantly correlated with the strength of 
the placebo effect in individual subjects in the left dorsolateral rostral pons (Table 10 and Figure 
15). Regions with the largest signal decrease following placebo were correlated with stronger 
behavioural change. No correlations were seen with the opposite contrast (placebo > control). 
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Table 10 – Brainstem Activations for Contrast Control > Placebo 
 
Control >Placebo 
Regions Activated MNI Coordinates (COG) Cluster p value Cluster Size (Voxels) 
 x y z   
Caudal Lateral Pons 
Rostral Ventrolateral 
Medulla 
Rostral Dorsolateral 
Medulla 
9 -39 -46 0.003 402 
Right Dorsolateral 
Caudal Pons 
21 -33 -41 0.013 111 
Right Dorsolateral 
Rostral Pons 
10 -38 -25 0.03 15 
Left Dorsolateral 
Caudal Pons 
-12 -44 -44 0.024 13 
Caudal Medulla 0 -42 -64 0.002 15 
      
Activation Correlated with Urge-to-Cough Ratings 
Regions Activated 
MNI Coordinates (COG) Cluster p value Cluster Size (Voxels) 
x y z   
Left Dorsolateral 
Rostral Pons 
-8 -43 -29 0.016 35 
 
Definition of abbreviations: See Table 9 for explanations.  
Clusters significant at p<0.05, corrected (FWE) and extent of >10 voxels. MNI co-ordinates 
correspond to centre of gravity (COG) of clusters. 
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Figure 15 - Regions where Decreased Activation following Placebo is Correlated with 
Behavioural Ratings 
 A) Sagittal cross-
section and B) coronal cross-section showing left dorsolateral rostral brainstem regions (in red) 
where the strength of the placebo effect (difference between ratings in control trials and ratings in 
placebo trials for each individual) was correlated with the contrast control>placebo. Activation in 
control>placebo contrast is shown in the background in green. Shown at visualisation threshold of 
p<0.005, uncorrected. Activation maps are overlaid on a standard MNI brain template. Images 
displayed in radiological convention (right side of brain is displayed on the left of the image). Lines 
indicate level of respective axial cross-sections. C) Axial cross-sections. 
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Discussion 
Summary 
The sensation of airway irritation termed the urge-to-cough is an important aspect of clinical 
respiratory pathophysiology (Davenport, 2009). The neural pathways involved in regulating sensory 
processing of afferent information from the airways have not yet been investigated in detail in 
humans. This study provides evidence that this processing can be inhibited even at the earliest 
stages of afferent input to the CNS. 
 
This is the first indication that placebo can cause descending inhibition of sensory processing of 
afferent input from the airways at the level of the brainstem. These regulatory regions in the pons 
and medulla may have potential as targets in developing future treatments for chronic cough 
disorders, or for assessing the efficacy of potential antitussive therapies. 
 
The administration of a placebo affected both cortical and subcortical processing of the urge-to-
cough. Confirming the results of the previous study (Leech et al., 2013), placebo treatment was 
associated with significant decreases in capsaicin-related activation in a distributed network of 
cortical regions normally involved in sensing airway irritation. Furthermore, this decrease in 
activation was also apparent in respiratory-related subcortical regions, implying that simply the 
belief and expectation of receiving a treatment can cause inhibition at the first central sites where 
sensory information from the airways is integrated.  
 
Placebo Suppression of the Urge-to-Cough 
Unlike the previous studies, we did not see a placebo related decrease in urge-to-cough ratings in all 
participants. 14 out of 16 participants rated their urge-to-cough as lower on average following 
placebo. The mean difference in ratings between placebo and control conditions for all participants 
was still highly significant and again reflects a high rate of placebo response when compared to 
placebo effects in other systems (Benedetti, 2008; Hróbjartsson & Gøtzsche, 2004b). 
 
Similar to the previous studies, high doses were on average one quarter of the C2 dose, however 
this did vary widely between subjects. This is likely to reflect the difference between single 
maximal inhalation challenges used to measure C2, and the experimental protocol that involved 16 
second non-maximal inhalation periods. Similarly, the low dose was occasionally below the Cu in 
some individuals, reflecting the greater sensitivity to near perceptual threshold during continuous 
inhalation periods. 
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Brainstem Activity Associated with Placebo Suppression of the Urge-to-Cough 
There was a significant reduction in capsaicin-related signals following placebo in widespread 
regions of the pons and medulla that are presumably related to relaying sensory information from 
the airways. During control trials, there was significant widespread bilateral activation in the 
medulla and pons, while during placebo trials this activation was limited to a circumscribed region 
in the right caudal medulla. The spatial pattern of capsaicin-induced activation seen in placebo trials 
was however similar to control trials at a lower statistical threshold, indicating that while signal 
change associated with neural activity in the placebo condition was not abolished, it was greatly 
reduced. 
 
As there were no areas that showed significantly increased activation following placebo treatment, 
it is not possible to define precisely where this inhibition occurs. However, the widespread decrease 
in BOLD signals throughout the pons and rostral medulla suggests that inhibition is occurring at the 
level of the caudal medulla. Given the evidence pointing to the caudal nTS as a potential site for 
modulation of incoming sensory signals from the airways (Boscan et al., 2002; Canning & Mori, 
2010), and the fact that the nTS receives input from cortical regions including the prefrontal cortex 
(Otake & Nakamura, 2003; Van Der Kooy et al., 1982; Vanderkooy et al., 1984), makes the nTS a 
likely candidate region for the cortico-medullary descending inhibition observed in this study. A 
region where activation strength and behavioural measures were correlated was also seen in the 
rostral dorsolateral pons, at the level of the pontine respiratory group, indicating that this region 
may also be involved in orchestrating the placebo response. 
 
The limited amount of information about functional brainstem anatomy in humans, as well as issues 
of registration, precludes definitive identification of specific regions of activation. Variation in 
brainstem orientation and size between individuals makes registration to a group template 
challenging, and available tools are not optimised for the brainstem (Napadow et al., 2006). These 
results must be considered preliminary until more detailed studies of the functional anatomy of 
respiratory centres have been carried out. Future studies of cough sensory pathways in the 
brainstem using high-field MRI may lead to improved localisation of specific nuclei.  
 
Similarity to Placebo Analgesia 
This study points to similarities in the mechanisms of placebo suppression of the urge-to-cough and 
placebo analgesia. Studies have shown decreased pain-related activation following placebo in spinal 
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cord nuclei (Eippert et al., 2009a; Eippert et al., 2009b). Considering that similar cortical regions 
are recruited during placebo analgesia and placebo inhibition of urge-to-cough, it would appear that 
an analagous process of descending inhibition occurs, involving DLPFC and PPC and affecting 
activity even at the earliest level of central processing. Although this does not rule out the 
possibility of cortico-cortical inhibition also playing a role in placebo suppression of urge-to-cough, 
it does indicate that, at least experimentally, it is possible to suppress processing of urge-to-cough 
sensory signals in the brainstem by behavioural manipulation. Furthermore, the decrease in 
activation was correlated with behavioural measures, indicating that these regions play a functional 
role in urge-to-cough suppression. 
 
Conclusions 
Placebo antitussive treatment produces significant behavioural decreases in urge-to-cough that are 
associated with reduced activation in cortical regions normally activated by capsaicin inhalation. 
Results from this study show that inhibition of urge-to-cough sensory processing is also apparent in 
the subcortex, with decreased activation following placebo seen in the pons and rostral medulla.  
This indicates that placebo inhibition of the urge-to-cough involves descending inhibition of 
brainstem regulatory regions related to respiration and airway control. It is likely that changes in 
these endogenous inhibitory circuits are involved in disorders of abnormal or excessive cough. 
Future research into the functional organisation of sensory processing of airway irritation in the 
brainstem may lead to novel insights into the neural basis of cough sensitisation as well as 
providing targets for antitussive therapies aimed at reducing the urge-to-cough.
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Chapter 6 - CONCLUSION 
 
Summary of Findings 
Abnormal urge-to-cough is a common medical condition with few effective treatments. Research 
has traditionally focused on the motor reflex aspect of cough rather than the sensation of urge-to-
cough itself. Targeting this sensation may be a more safe and effective form of treatment than 
targeting the cough reflex, which is necessary for the maintenance of healthy airways. These studies 
used placebo treatment to manipulate the sensation of urge-to-cough while participants received the 
same input from the airways (i.e. the same stimulus intensity), allowing for the identification of 
local changes in brain activity associated with suppression of the urge-to-cough. These regions 
constitute potential targets for developing future antitussives. Additionally, investigation of the 
neural correlates of placebo inhibition in urge-to-cough may help to explain reports of substantial 
placebo effects associated with antitussive therapy (Eccles, 2002). 
 
Research into urge-to-cough has been limited due to the difficulty of examining this phenomenon in 
animal models. While animal studies of cough have been invaluable in basic physiological research 
on reflex cough, and in defining the afferent pathways involved in conveying sensory information 
from the airways, the sensory aspect of urge-to-cough has been largely ignored, even though this is 
often the primary complaint in patients with chronic cough disorders. 
 
Evidence for a strong placebo component in cough treatment has been accumulating over the last 
few decades, however, until now no direct experimental evidence has existed to attempt to quantify 
this effect. This is the first evidence that placebos dramatically reduce the experimentally induced 
urge-to-cough in healthy human volunteers.  
 
Experimentally Induced Placebo Effect in Urge-to-Cough 
The first study (Chapter 3) showed that a placebo effect on urge-to-cough could be induced and 
quantified under experimental conditions. Despite repeated speculation on the role of placebo 
effects in cough, this is the first attempt to experimentally measure the effect of placebo on the 
sensation of airway irritation. Conditioning combined with the expectation of successful treatment 
substantially reduced self-reported ratings of the urge-to-cough in response to capsaicin challenge. 
This effect was consistently observed in all participants. This outcome suggests that higher brain 
networks can modulate central processing of input from the airways. 
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Regional Cortical Activation Associated with Placebo Effect in Urge-to-Cough 
Results from the second study (Chapter 4) indicate that placebo treatment not only modifies 
behavioural measures of urge-to-cough, but also reduces capsaicin-induced activation in the cortex. 
Significant decreases in activation were seen in a network of regions normally activated during 
capsaicin inhalation, including somatosensory, primary motor, insula and cingulate cortices. 
Following placebo, increases in activation were seen in prefrontal and left posterior parietal 
cortices, and the magnitude of activation in the right DLPFC was correlated with the magnitude of 
behavioural changes in urge-to-cough ratings, suggesting that these regions are implicated in the 
sensory modification of urge-to-cough following placebo. 
 
Brainstem Activation Associated with Placebo Inhibition of Urge-to-Cough 
Corresponding with a significant placebo induced reduction in behavioural measures of urge-to-
cough, there were also significant decreases in activation in a network of respiratory related regions 
in the brainstem (Chapter 5). A subset of these areas also showed correlations between the strength 
of the observed placebo effect and the decrease in activation during placebo trials. Placebo induced 
decreases in activation were observed in all regions superior to the caudal medulla, indicating the 
presence of endogenous inhibitory circuits in the brainstem that are capable of suppressing the 
processing of incoming sensory information from the airways before it reaches the cortex.  
 
Implications of Studies 
The magnitude of the placebo effect in capsaicin induced urge-to-cough provides further support for 
the contention there is a high rate of response to placebo in clinical trials of antitussives. Alternative 
models for clinical trials may provide a more accurate representation of the true effects of 
antitussives without simply recruiting more patients. For instance, sequential parallel comparative 
trials (Heger, 2013), or trial designs incorporating appropriate active placebos. These results also 
suggest that retrospective testing of antitussives that were approved before the advent of double-
blind placebo-controlled clinical trials may be desirable. As has been suggested previously, lack of 
information about the effectiveness of treatments compared to placebo may lead to unnecessary 
costs for both consumers and healthcare providers (Schroeder & Fahey, 2004), as well as the 
potential for unnecessary exposure to side effects. Additionally, comparing new antitussives to 
currently available treatments may inflate the benefits of the new treatment if insufficient evidence 
exists that the currently available treatment is any more effective than a placebo. 
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Limitations of Experimental Methods and Future Directions for Research 
These studies were limited to experimental cough induced by capsaicin. Although this is the most 
common experimental method of inducing cough, other methods such as fog, citric acid and 
mechanical stimulation are available (Dicpinigaitis, 2007). Contrasting placebo effects in other 
forms of inducible cough would be a useful step both to cross-validate these results, and to 
investigate whether other forms of cough may respond differently to placebo treatment.  
 
Similarly, experimentally induced cough may involve different physiological mechanisms to 
spontaneous cough (Dicpinigaitis, 2007). While there is evidence that placebo effects may play a 
part in the effectiveness of many antitussives (Eccles et al., 1992; Freestone & Eccles, 1997; 
Schroeder & Fahey, 2004; Taylor et al., 1993), this has not been studied systematically. A logical 
next step would be to examine placebo responses in patients with cough disorders. As evidence 
suggests that sensitisation of central pathways may be involved in chronic cough (Bolser, 2004; 
Morice & McGarvey, 2009; Widdicombe & Singh, 2006), contrasting the effect of placebo in 
patients with acute cough (such as cough associated with upper respiratory tract infections) and 
patients with chronic cough may help to shed light on the underlying mechanisms involved in 
cough sensitisation. 
 
This series of studies has produced novel insights into the functional brain correlates of placebo 
effects in urge-to-cough. Other analysis techniques would be particularly suited to further 
investigating these effects. Placebo analgesia studies incorporating neuroimaging have now begun 
to tease apart various aspects of placebo induced pain suppression. For instance, the relative 
contributions of expectation and conditioning (Benedetti et al., 2003; Stewart-Williams & Podd, 
2004), opioidergic versus non-opioidergic pathways (Scott et al., 2008) and investigation of regions 
that are activated during the anticipation of painful stimulus (Wager, Atlas, Leotti, & Rilling, 2011; 
Wager et al., 2004; Watson et al., 2009). These techniques all have the potential to further advance 
knowledge of the neurobiological basis of the effect of placebo on the urge-to-cough. In addition, 
investigation of functional connectivity between prefrontal cortex and respiratory nuclei in the pons 
and medulla may lead to insights into the functional organisation of placebo-induced urge-to-cough 
suppression. 
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Conclusions 
The aim of this research was to establish whether administration of a placebo antitussive could 
reduce capsaicin-induced urge-to-cough in healthy volunteers, and to identify cortical and 
subcortical brain regions that are involved in modulating the urge-to-cough.  
 
The results from these studies show that the urge-to-cough is indeed modifiable by placebo, 
indicating that higher brain regions are involved in regulating the processing of afferent sensory 
information from the airways. Placebo suppression is associated with reduced activity in a network 
of brain regions involved in sensory perception of the urge-to-cough, and with increased activity in 
regions in the frontal and parietal cortices. Furthermore, placebo inhibition of capsaicin-induced 
urge-to-cough is associated with reduced activity in respiratory centres in the pons and rostral 
medulla, indicating that this modulation involves descending inhibition. 
 
This research adds to the evidence that perception of airway irritation is a complex process 
involving distributed cortical and subcortical networks. Manipulating the processing of urge-to-
cough by placebo treatment is a novel method of investigating endogenous inhibitory mechanisms 
that may provide opportunities for future research aimed at potential antitussive therapies that target 
the sensation of urge-to-cough rather than disrupting reflex cough. 
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XYLOCAINE(R) 4%
TOPICAL SOLUTION
Lignocaine Hydrochloride
Consumer Medicine Information
What is in this leaflet
This leaflet answers some of the
common questions people ask about
Xylocaine 4% Topical Solution
(Xylocaine Topical) .  It does not
contain all the information that is
known about Xylocaine Topical. 
It does not take the place of talking
to your doctor or pharmacist. 
All medicines have risks and
benefits. Your doctor has weighed
the risks of you using Xylocaine
Topical against the benefits they
expect it will have for you. 
If you have any concerns about
using this medicine, ask your
doctor or pharmacist. 
Keep this leaflet. 
You may need to read it again. 
What XYLOCAINE
TOPICAL is for
Xylocaine Topical is used to produce
temporary loss of sensation in a part
of the body before certain types of
examination and instrumentation are
performed by your doctor, such as an
examination of your throat or lungs.
It may also help prevent coughing or
gagging during these procedures. 
Xylocaine Topical belongs to a
group of medicines called local
anaesthetics. It works by making the
pain nerves unable to send messages
to the brain. 
Ask your doctor or pharmacist if
you have any questions about why
Xylocaine Topical is being used for
you. 
Your doctor may be using it for
another reason. 
Xylocaine Topical is not addictive. 
Before you use
XYLOCAINE TOPICAL 
When you must not use it
Do not use Xylocaine Topical if
you have an allergy to: 
* the active ingredient, lignocaine
* any other local anaesthetics
* para aminobenzoic acid (PABA) 
* any of the ingredients listed at the
end of this leaflet. 
Some of the symptoms of an allergic
reaction may include: 
* shortness of breath
* wheezing or difficulty breathing
* swelling of the face, lips, tongue
or other parts of the body, 
* rash itching or hives on the skin. 
Xylocaine Topical should not be
used after the expiry date printed
on the pack or if the packaging is
torn or shows signs of tampering. 
If it has expired or is damaged, return
it to your pharmacist for disposal. 
Xylocaine Topical should not be
used on open wounds or infected
areas. 
If you are not sure that you should
be using this medicine talk to your
doctor or pharmacist. 
Before you start to use it
Tell your doctor or pharmacist if
you have any allergies to any other
medicines, foods preservatives or
dyes. 
Tell your doctor or pharmacist if
you have or have had any of the
following medical conditions: 
* epilepsy
* heart problems
* liver problems
* kidney problems
* open wounds or infection where
the solution will be used
* dangerously high body
temperature or if you have a
family history of dangerously
high body temperature
* porphyria ( a rare metabolic
disorder characterised by
excessive levels of porphyrin in
the blood and urine) Symptoms
of acute porphyria include: 
- muscle pain or paralysis
- seizures
- disorientation
- hallucination
- bloody (red) urine
- hypertension
- abdominal pain
- constipation
- vomiting. 
Tell your doctor or pharmacist if
you are pregnant or plan to
become pregnant  or are
breast-feeding or plan to 
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breast-feed. 
Your doctor can discuss the risks and
benefits involved. 
Taking other medicines
Tell your doctor or pharmacist if
you are taking any other
medicines, including any medicines
that you get without a prescription
from your pharmacy supermarket
or health food shop. 
Some medicines and Xylocaine
Topical  may interfere with each
other.  These include: 
* medicines used to treat irregular
heart beat
* cimetidine, a medicine used to
help reduce the amount of acid
produced by the stomach
* medicines used to treat epilepsy
such as, phenytoin,
phenobarbitone, primodone and
carbamazepine. 
These medicines may be affected by
Xylocaine Topical or may affect how
well it works.  You may need
different amounts of your medicines
or you may need to use different
medicines. 
Your doctor and pharmacist have
more information on medicines to be
careful with or avoid while using this
medicine. 
If you have not told your doctor or
pharmacist about any of these
things, tell them before you are
given any Xylocaine Topical. 
Using XYLOCAINE
TOPICAL 
How to use it
Xylocaine Topical will usually be
administered  by your doctor. 
The dose of Xylocaine Topical
depends on the procedure that your
doctor will be performing.  Your
doctor will use the dose that is
suitable for you.  The dose normally
used in adults is 1-5mL of Xylocaine 
Topical solution (40 - 200mg
lignocaine hydrochloride). 
Children are given a lower dose,
depending on the age and weight of
the child.  The usual maximum dose
does not exceed 3 mg/kg of
bodyweight. 
Xylocaine Topical can be applied
with a cotton swab or pack, or
directly onto the area. 
Xylocaine Topical is sometimes used
as a spray during procedures
involving the throat and windpipe. 
Overdose
Telephone your doctor or the
Poisons Information Centre (13 11
26) or go to Accident and
Emergency at your nearest
hospital immediately if you think
that you or anybody else may have
used too much Xylocaine Topical
even if there are no signs of
discomfort or poisoning. 
The first signs that too much
Xylocaine Topical has been used are
light headedness, drowsiness,
dizziness, and sometimes blurred
vision.  In the event of a serious
overdosage, trembling, seizures or
unconsciousness may occur. 
While you are using it
Things to be careful of 
Be careful driving or operating
machinery after you have been
given Xylocaine Topical. 
You may be drowsy and your
reflexes may be slow. If you have
any of these symptoms, do not drive,
operate machinery or do anything
else that may be dangerous. 
Things you must not do
Do not eat or drink anything for at
least 1 hour after you have been
given Xylocaine Topical in the
mouth or throat area. 
You may swallow your food the 
wrong way, or burn or bite your
mouth.  Eating, chewing or drinks
should be avoided while the mouth or
throat is numb. 
Do not use Xylocaine Topical as a
gargle. 
Contact with Xylocaine Topical
and your eyes  should be avoided. 
If any of the solution does go in your
eye, rinse immediately with lots of
water for at least 15 minutes and call
your doctor. 
Side effects
Tell your doctor or pharmacist as
soon as possible if you do not feel
well after you  have been given
Xylocaine Topical. 
All medicines can have side effects.
Sometimes they are serious, most of
the time they are not.  You may need
medical treatment if you get some of
the side effects. 
Do not be alarmed by the following
list of side effects.  You may not
experience any of them. 
Ask your doctor  or pharmacist to
answer any questions you may
have. 
Tell your doctor  if you notice any
of the following and they worry
you: 
* skin rash or irritation
These side effects are usually mild. 
Tell your doctor immediately or go
to Accident and Emergency at
your nearest hospital if you notice
any of the following: 
* dizziness, lightheadedness 
* drowsiness, confusion
* blurred vision, ringing in the ears
* tremor
* wheezing or difficulty breathing
* chest pain
* severe rash or itching
* increased sweating
* fits
* unconsciousness
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* low blood pressure
* slow heart beat
* collapse. 
These are very serious side effects.
You may need urgent medical
attention or hospitalisation. 
All of these side effects are rare. 
Tell your doctor if you notice
anything that is making you feel
unwell. 
Other side effects not listed above
may occur in some people. 
Storage
Keep your Xylocaine Topical in the
bottle until it is time to use it. 
Keep it in a cool place where the
temperature is kept below 25
degrees C. 
Do not store it or any other
medicine in the bathroom or near a
sink.  Do not leave it in the car or
on a window sill. 
Heat and dampness can destroy some
medicines. 
Keep it where young children
cannot reach it. 
A locked cupboard at least
one-and-a-half metres above the
ground is a good place to store
medicines. 
Disposal
Ask your pharmacist what to do
with any solution you have left
over if your doctor tells you to stop
using it, or you find that the expiry
date has passed. 
Product description
Xylocaine Topical is a clear,
colourless solution in bottles of
30mL. 
Each mL of solution contains 40 mg
lignocaine hydrochloride
(anhydrous) and the following
inactive ingredients: 
* Methyl hydroxybenzoate (E 218) 
* Sodium hydroxide or
hydrochloric acid (for pH
adjustment) 
* Purified water . 
Lignocaine is known as lidocaine in
some other countries. 
Sponsor
AstraZeneca Pty Ltd
ABN 54 009 682 311
Alma Road
NORTH RYDE  NSW  2113
This leaflet was prepared in 
March 2009
Customer service line: 
Tel: 1 800 805 342
Australian Registration Number
Xylocaine 4% Topical Solution
AUST R 124858
Xylocaine is a  registered trade mark
of  the AstraZeneca Group of
companies. 
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Pre Scan Questionnaire 
 
 
Did your urge-to-cough decrease following the lidocaine treatment? 
 
Substantially  Somewhat  Not Noticeably  Increased 
 
 
Did your urge-to-cough change from the beginning to the end of each capsaicin inhalation 
period? 
 
Increased  Decreased  No change 
 
 
Did your urge-to-cough change from the beginning to the end of the session? 
 
Increased  Decreased  No change 
 
 
Did the reduction in your urge-to-cough after lidocaine treatment change from the beginning 
to the end of the session? 
 
Increased  Decreased  No change 
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Post Debriefing Questionnaire 
 
 
Did you have any suspicions prior to beginning the experiment that there was a placebo 
involved? 
 
Yes No  
 
If Yes, what made you suspicious? 
 
 
 
 
 
Did you have any suspicions during the experiment you were not actually receiving lidocaine? 
 
Yes  No 
 
If Yes, what made you suspicious? 
 
 
 
 
 
 
 
Had you heard anything about this study or known anyone else who participated before you 
attended the session? 
 
Yes  No 
 
 
 
